### Check for updates

#### **OPEN ACCESS**

EDITED BY Shalini Mani, Jaypee Institute of Information Technology, India

### REVIEWED BY John W. Yuen, Hong Kong Polytechnic University, Hong Kong SAR, China

Xinglong Yang, The First Affiliated Hospital of Kunming Medical University, China

\*CORRESPONDENCE Ning Li ⊠ ln960\_gerontology@163.com Wei Wei ⊠ 397451715@qq.com

RECEIVED 24 November 2024 ACCEPTED 02 June 2025 PUBLISHED 02 July 2025

#### CITATION

Xu Y, Wang X, Wang G, Wei W and Li N (2025) Relationship between nocturia, depression, and cognitive function and the mediating effects of nutritional indexes in older adults: data from NHANES 2011–2014. *Front. Nutr.* 12:1533683. doi: 10.3389/fnut.2025.1533683

#### COPYRIGHT

© 2025 Xu, Wang, Wang, Wei and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Relationship between nocturia, depression, and cognitive function and the mediating effects of nutritional indexes in older adults: data from NHANES 2011–2014

### Yin Xu<sup>1</sup>, Xinmei Wang<sup>2</sup>, Guofeng Wang<sup>1</sup>, Wei Wei<sup>1\*</sup> and Ning Li<sup>1\*</sup>

<sup>1</sup>Department of Gerontology, The 960th Hospital of PLA, Jinan, China, <sup>2</sup>The Academy of Military Medical Sciences of China, Beijing, China

**Purpose:** This study evaluated the correlation between nocturia, depression, and cognitive function in older adults and the mediating effect of albumin and hemoglobin on this correlation.

**Methods:** Data on nocturia, depression, and cognitive function from the National Health and Nutrition Examination Survey 2011–2014 were analyzed by multiple logistic regression.

**Results:** The digit symbol score (DSS) and 9-Item Patient Health Questionnaire (PHQ-9) scores were linearly and non-linearly correlated with nocturia risk (p < 0.05). Male/female-stratified analysis showed that animal fluency scores (AFS), DSS, and PHQ-9 scores were significantly correlated with the risk of nocturia in females (p < 0.05), and PHQ-9 scores were significantly associated with the risk of nocturia in females (p < 0.05). Albumin partially mediated the association of AFS, DSS, and PHQ-9 scores with nocturia risk in women and the relationship of PHQ-9 scores with nocturia risk in men. Hemoglobin partially mediated the relationship of PHQ-9 scores with nocturia risk in women and the association of PHQ-9 scores with nocturia risk in men.

**Conclusion:** Nocturia is positively associated with depression and cognitive impairment in older adults, especially in women. Nutrition partially mediates the relationship between nocturia, depression, and cognitive function. Thus, improving nutrition may decrease the risk of nocturia in older adults.

KEYWORDS

nocturia, cognitive function, depression, older adults, albumin, hemoglobin

# **1** Introduction

Nocturia, defined as waking at night to void, is a prevalent condition affecting a significant proportion of the adult population and is increasingly recognized as a multifaceted syndrome with systemic health implications (1–4). Emerging evidence underscores bidirectional associations between nocturia and neuropsychiatric disorders, particularly depression and cognitive dysfunction, mediated through interconnected pathophysiological pathways. For instance, depression severity demonstrates a dosedependent relationship with nocturia, with studies indicating heightened depression risk in individuals affected by nocturia (5, 6). Similarly, cognitive dysfunction is also linked to nocturia, as systematic reviews report significant associations between the two conditions, though causal inferences are limited by the predominance of cross-sectional designs (4). The underlying mechanisms involve disruptions in the hypothalamic-pituitary-adrenal (HPA) axis, circadian rhythm disturbances, and inflammatory cascades. HPA axis hyperactivity, often observed in depression, elevates the secretion of proinflammatory cytokines such as IL-6 and TNF- $\alpha$ , impairing neuroplasticity and contributing to neuropsychiatric symptoms (7, 8). Sleep fragmentation, a common feature of nocturia, exacerbates HPA axis dysregulation and reduces amyloid-beta clearance efficiency, thereby accelerating cognitive decline (9, 10). Additionally, circadian misalignment and alterations in the tryptophan-kynurenine pathway contribute to neurotoxicity through excitotoxicity and oxidative stress, with dysregulated metabolites implicated in depressive pathology (11–14).

Nutritional status acts as a critical modulator in this network, with aberrant expression of serum albumin (Alb) and hemoglobin exacerbating neuropsychiatric outcomes. Specifically, reduced Alb and hemoglobin levels are associated with increased inflammation and oxidative stress, which amplify neurotoxic cascades and compromise blood-brain barrier function (13, 15, 16). Hypoalbuminemia and anemia may also impair neuroprotective pathways, while imbalances in the kynurenine pathway elevate quinolinic acid concentrations, leading to NMDA receptor-mediated excitotoxicity (12–14). Causal mediation analyses suggest nutritional biomarkers contribute up to 21.9% of associations between muscle-related factors and depressive symptoms, highlighting their potential as mechanistic bridges (13, 16).

Despite these advances, critical knowledge gaps persist. Current research relies heavily on cross-sectional data, precluding causal inference and limiting the exploration of temporal dynamics (4, 17). Non-linear dose-response relationships between nocturia severity, depression, and cognitive dysfunction remain underexplored, and sex-specific pathophysiological differences (e.g., gender disparities in biomarker profiles) are inadequately characterized (6). Furthermore, the role of nutritional mediators, such as serum Alb and hemoglobin, in bridging urinary dysfunction with neuropsychiatric outcomes requires deeper investigation through advanced methodologies like restricted cubic splines (RCS) and formal causal mediation analysis (4, 13). To address these gaps, this study employs a comprehensive analytical framework integrating multivariate logistic regression, RCS for modeling nonlinear effects, and causal mediation analysis. Building on prior epidemiological findings (4, 9), we aim to: (1) quantify independent associations between nocturia, depression severity, and cognitive dysfunction in at-risk populations; (2) characterize non-linear dose-response patterns using RCS, adjusted for demographic and behavioral confounders; (3) evaluate the mediating roles of serum Alb and hemoglobin in these associations; and (4) investigate sexand age-stratified effect modifications. Our findings are expected to elucidate nutritional biomarkers as pivotal factors in the nocturia-neuropsychiatric nexus, informing targeted interventions for vulnerable cohorts.

# 2 Methods

# 2.1 Study population

This study analyzed data from National Health and Nutrition Examination Survey (NHANES) 2011–2014. A detailed description of the data collection method can be found on the NHANES website (https://wwwn.cdc.gov/nchs/nhanes/Default.aspx). Two data cycles (2011–2014) involving 2,879 participants (48.6% males and 51.4% females) were analyzed. The exclusion criteria were participants younger than 60 years and participants with missing data on nocturia frequency, blood test results, body mass index, arterial blood pressure, glycosylated HGB levels, physical activity, smoking status, and drinking status. The flowchart of patient selection is shown in Figure 1.

# 2.2 Nocturia

Data on the number of times the participants woke up at night to void were obtained by trained interviewers at the Mobile Examination Center (MEC) using the CAPI system. Nocturia was defined as at least two voids per night. Details on the administration of the questionnaire can be found in the MEC Interviewer Exam Manual.

# 2.3 Depression and cognitive function

The frequency of depressive symptoms over the past 2 weeks was measured using the 9-item Patient Health Questionnaire (PHQ-9). Cognitive function was assessed using word learning and recall modules, the animal fluency test, and the digit symbol substitution test (DSST). The CERAD word learning subtest assesses the immediate and delayed ability to learn new verbal information (memory subdomain). The test consists of three consecutive learning trials and a delayed recall. The immediate recall score (IRS) was calculated by summing the scores of three successive trials. The total word recall score (TWRS) was calculated by summing IRS and the delayed word recall score (DWRS). In order to reduce Category 1 errors, we selected total score (TWRS) instead of sub-score (IRS and DWRS) to study the correlation between nocturia and cognition (18, 19). The animal fluency test examined language fluency by asking the participants to name as many animals as possible in 1 min. The score was recorded as the animal fluency score (AFS). The DSST is a module of the Wechsler Adult Intelligence Scale that assesses processing speed, sustained attention, and working memory. In the DSST, participants are asked to substitute each number with a symbol within 120 s. The maximum possible score is 133 points. The digit symbol score (DSS) was the total number of correct answers. The cognitive function score was standardized into Z-score, which served as a metric for classifying the level of cognitive function (20). Z-score

Abbreviations: ACME, Average Causal Mediated Effect; ALB, albumin; AFS, animal fluency score; DSS, digit symbol scores; DSST, digit symbol substitution test; DWRS, delayed word recall score; HGB, hemoglobin; IRS, immediate recall score; MEC, Mobile Examination Center; NHANES, National Health and Nutrition Examination Survey; NMDA, N-methyl-D-aspartic acid; PHQ-9, Nine-Item Patient Health Questionnaire; PIR, Ratio of family income to poverty; PLA, People's Liberation Army; PMM, Pattern mixture model; TWRS, total word recall score.



 $\leq$  -1.5 SD is generally considered the threshold for mild cognitive impairment (MCI), while the normal range is defined as *Z*-score  $\geq$  -1.0 SD (21, 22).

## 2.4 Nutritional index

Blood counts and biochemical tests were used to measure serum ALB and glycosylated HGB, respectively. Blood samples were collected, processed, frozen at  $-20^{\circ}$ C, and sent to the Collaborative Laboratory Services for analysis. Comprehensive guidelines on specimen collection and processing are available in the NHANES Laboratory Procedures Manual.

# 2.5 Covariates

All covariates were selected through single-factor analysis (23– 26). Angina, congestive heart failure, coronary heart disease, type 2 diabetes mellitus, or stroke were considered chronic diseases. The participants were categorized into three groups based on smoking status: never smokers, former smokers, and current smokers. Never smokers were individuals who had never smoked or had smoked fewer than 100 cigarettes in their lifetime. Former smokers were those who had smoked at least 100 cigarettes but quit smoking (27). Drinkers were defined as individuals who consumed at least 12 drinks in 12 months. Blood pressure was measured consecutively three times by a medical professional using a sphygmomanometer, and the readings were averaged. Hypertension was defined as average systolic blood pressure  $\geq$ 140 mmHg or diastolic blood pressure  $\geq$ 90 mmHg. T2DM was defined by being diagnosed by a health professional or having HbA1c levels of  $\geq$ 6.5% or fasting glucose  $\geq$ 7.0 mmol/L (28).

## 2.6 Statistical analyses

Data were weighted according to NHANES requirements to be representative of the general population in the United States. The NHANES 2011-2014 data modules utilized in this study were sourced from the official public database of the Centers for Disease Control and Prevention (CDC). The data ownership resides with the United States Department of Health and Human Services (HHS). Researchers acquire these data by adhering to the standard data usage protocol, without requiring additional authorization. All analyses were performed using EmpowerStats statistical software (X&Y Solutions, Boston, MA) and R software version 4.3.2. In this study, multiple interpolation filling was performed on the missing values. After interpolation, the data integrity was examined, respectively, the distribution before and after interpolation was compared, the rationality of the interpolation values was checked, and the sensitivity analysis of different interpolation methods (PMM, random forest, Bayesian regression) and the diagnosis of interpolation models were conducted. Subsequent analysis is conducted using the interpolated data. Continuous variables were expressed as median (P25, P75), and categorical variables

### 10.3389/fnut.2025.1533683

### TABLE 1 Demographic characteristics of the cohort.

Characteristic	No nocturia	Nocturia	<i>p</i> -Value
Ν	1,555	1,324	
Age [years, median (IQR)]	68.00 (63.00-74.00)	69.00 (64.00-76.00)	< 0.001
Male/female (%)			0.592
Male	749 (48.17%)	651 (49.17%)	
Female	806 (51.83%)	673 (50.83%)	
Race/ethnicity (%)			< 0.001
Mexican American	122 (7.85%)	128 (9.67%)	
Other Hispanic	154 (9.90%)	141 (10.65%)	
Non-Hispanic White	836 (53.76%)	542 (40.94%)	
Non-Hispanic Black	295 (18.97%)	385 (29.08%)	
Other race	148 (9.52%)	128 (9.67%)	
Education level (%)			< 0.001
Less than high school	309 (19.87%)	414 (31.34%)	
High school graduate/GED or equivalent	347 (22.32%)	326 (24.68%)	
College or above	899 (57.81%)	581 (43.98%)	
Marital status (%)			< 0.001
Married/living as married	954 (61.39%)	708 (53.60%)	
Single/divorced/widowed/ never married	600 (38.61%)	613 (46.40%)	
Body mass index [kg/m <sup>2</sup> , median (IQR)]	27.60 (24.30–31.40)	28.60 (25.00-33.20)	< 0.001
PIR [median (IQR)]	2.59 (1.33-4.92)	1.88 (1.04–3.38)	< 0.001
Drinking status (%)			0.003
No	458 (29.47%)	458 (34.64%)	
Yes	1,096 (70.53%)	864 (65.36%)	
Smoking status (%)			0.884
No	761 (48.97%)	655 (49.51%)	
Now	591 (38.03%)	504 (38.10%)	
Former	202 (13.00%)	164 (12.40%)	
Work activity (%)			< 0.001
Vigorous	188 (12.10%)	119 (9.00%)	
Moderate	332 (21.36%)	229 (17.32%)	
Other	1,034 (66.54%)	974 (73.68%)	
Recreational activity (%)	)		< 0.001
Vigorous	179 (11.51%)	89 (6.72%)	
Moderate	534 (34.34%)	402 (30.36%)	
Other	842 (54.15%)	833 (62.92%)	
Hypertension (%)			< 0.001
No	517 (34.33%)	300 (23.27%)	
Yes	989 (65.67%)	989 (76.73%)	

(Continued)

### TABLE 1 (Continued)

Characteristic	No nocturia	Nocturia	<i>p</i> -Value
Diabetes (%)			< 0.001
No	1,196 (77.06%)	905 (68.46%)	
Yes	356 (22.94%)	417 (31.54%)	
Immediate recall score	20.00	19.00	< 0.001
[median (IQR)]	(16.00–23.00)	(15.00–22.00)	
Delayed word recall score	6.00	6.00	< 0.001
[median (IQR)]	(5.00-8.00)	(4.00-7.00)	
Total word recall [median (IQR)]	26.00 (21.00-30.00)	25.00 (20.00–29.00)	< 0.001
Animal fluency score	17.00	16.00	< 0.001
[median (IQR)]	(13.00–21.00)	(12.00–19.00)	
Digit symbol score [median	49.00	42.00	< 0.001
(IQR)]	(37.00-61.00)	(30.00-54.00)	
PHQ-9 score [median	1.00	2.00	< 0.001
(IQR)]	(0.00-3.00)	(0.00-6.00)	
Hemoglobin [g/L, median	13.90	13.60	< 0.001
(IQR)]	(13.10–14.80)	(12.60–14.50)	
Albumin [g/L, median	4.20	4.20	<0.001
(IQR)]	(4.00-4.40)	(4.00-4.40)	

Data are median (P25, P75) or numbers and percentages.

p-Value: Kruskal–Wallis rank sum test for continuous variables, Fisher exact test for categorical variables with expects <10.

TABLE 2 Multiple regression analysis of the association of cognitive function and depression scores with the risk of nocturia in older adults.

Exposure	Non- adjusted	Model I	Model II
Immediate recall scores	0.9534 (0.9382, 0.9688), <i>p</i> < 0.000001	0.9821 (0.9638, 1.0008), p = 0.060652	$\begin{array}{c} 0.9819 \ (0.9628, \\ 1.0015), \\ p = 0.069880 \end{array}$
Delayed word recall scores	0.9398 (0.9104, 0.9701), p = 0.000126	1.0068 (0.9697, 1.0453), <i>p</i> = 0.722962	1.0028 (0.9642, 1.0430), p = 0.887868
Total word recall scores	0.9686 (0.9576, 0.9796), p < 0.000001	0.9916 (0.9782, 1.0051), <i>p</i> = 0.221534	$\begin{array}{c} 0.9910 \ (0.9770, \\ 1.0051), \\ p = 0.209903 \end{array}$
Animal fluency scores	0.9469 (0.9338, 0.9602), <i>p</i> < 0.000001	0.9827 (0.9667, 0.9990), p = 0.037828	$\begin{array}{c} 0.9853 \ (0.9684, \\ 1.0025), \\ p = 0.092566 \end{array}$
Digit symbol scores	0.9752 (0.9708, 0.9796), <i>p</i> < 0.000001	$\begin{array}{c} 0.9876 \ (0.9814, \\ 0.9939), \\ p = 0.000108 \end{array}$	$\begin{array}{c} 0.9890 \ (0.9824, \\ 0.9958), \\ p = 0.001430 \end{array}$
9-item patient health questionnaire scores	1.0879 (1.0684, 1.1078), <i>p</i> < 0.000001	1.0823 (1.0606, 1.1043), <i>p</i> < 0.000001	1.0749 (1.0525, 1.0978), <i>p</i> < 0.000001

Model I was adjusted for male/female, age, race, education level, marital status, and poverty-to-income ratio.

Model II was adjusted for male/female, age, race, education level, marital status, and povertyto-income ratio, body mass index, hypertension, diabetes, smoking status, alcohol drinking status, work activities, and recreational activities.

were expressed as percentages. If the variable was continuous, the Kruskal–Wallis rank-sum test was employed. For counting variables with a theoretical value <10, the Fisher's exact probability

test was utilized. The analysis process was done by Empowerstats. The participants were divided into two groups based on the presence or absence of nocturia. The relationship between nocturia, depression, and cognitive function was evaluated using multivariate logistic regression analysis and restricted cubic splines. We adjusted for covariates and performed multiple regression analyses. The results were stratified by male/female, and sensitivity analysis was performed. The mediating effect of ALB and HGB on the association between nocturia, depression, and cognitive function was assessed using the mediation package in R (Bootstrap = 5,000, prop. mediated = ACME (average)/total effect) (29). All RCS models were adjusted for male/female, age, race, education level, marital status, PIR, BMI, hypertension, diabetes, smoking

status, alcohol drinking status, work activities, and recreational activities as covariates. Subgroup analyses of male/female and age were used to study the stability and specificity of mediating effects. The Akaike Information Criterion (AIC) value was used to determine the optimal number of knots, the number of knots was three for DWRS (10, 50, and 90th percentiles) and PHQ-9 Score, and five for AFS and DSS (5, 25, 50, 75 and 95th percentiles). If the indirect effect was not significant (p > 0.05), the intermediate ratio was not calculated (30). In the sensitivity analysis, the correlation between cognitive function and nocturia was examined using multiple regression analysis after adjustment for confounding factors. *p*-Values of <0.05 were considered statistically significant.



# **3** Results

# 3.1 Participant characteristics

The study included 2,879 participants with a mean age of 69.44  $\pm$  6.77 years. The demographic and clinical characteristics of the study population are shown in Table 1. Nocturia was associated

with older age, Mexican American or non-Hispanic Black ethnicity, lower education, unmarried status, higher body mass index, lower poverty-to-income ratio, alcohol drinking, current smoking, higher engagement in work or recreational activities, and higher prevalence of diabetes and hypertension. Furthermore, nocturia was linked with lower DWRS, AFS, and DSS and higher PHQ-9 scores (p < 0.05).

TABLE 3 Association of cognitive function and depression scores with nocturia risk stratified by male/female.

Cognitive function and depression scores	Model	Males		Females	
		Odds ratio (95% confidence interval)	p-Value	Odds ratio (95% confidence interval)	<i>p</i> -Value
Total word recall score	Unadjusted	0.9711 (0.9546, 0.9879)	0.0008	0.9655 (0.9505, 0.9808)	<0.0001
	Model I	0.9973 (0.9775, 1.0174)	0.7896	0.9859 (0.9678, 1.0045)	0.1359
	Model II	0.9950 (0.9744, 1.0159)	0.6352	0.9869 (0.9678, 1.0064)	0.1873
Animal fluency score	Unadjusted	0.9603 (0.9418, 0.9792)	<0.0001	0.9329 (0.9143, 0.9519)	<0.000001
	Model I	0.9946 (0.9721, 1.0176)	0.6398	0.9686 (0.9458, 0.9921)	0.0090
	Model II	0.9952 (0.9717, 1.0193)	0.6929	0.9724 (0.9480, 0.9973)	0.0302
Digit symbol score	Unadjusted	0.9766 (0.9700, 0.9833)	<0.000001	0.9735 (0.9676, 0.9794)	<0.000001
	Model I	0.9893 (0.9797, 0.9989)	0.0294	0.9851 (0.9768, 0.9935)	0.0005
	Model II	0.9907 (0.9805, 1.0009)	0.0745	0.9863 (0.9773, 0.9955)	0.0034
9-item patient health questionnaire score	Unadjusted	1.1047 (1.0728, 1.1375)	<0.000001	1.0809 (1.0556, 1.1067)	<0.000001
	Model I	1.1109 (1.0759, 1.1471)	<0.000001	1.0606 (1.0328, 1.0890)	<0.0001
	Model II	1.0971 (1.0617, 1.1336)	<0.000001	1.0578 (1.0286, 1.0879)	<0.0001

Model I was adjusted for male/female, age, race, education level, marital status, and poverty-to-income ratio.

Model II was adjusted for male/female, age, race, education level, marital status, and poverty-to-income ratio, body mass index, hypertension, diabetes, smoking status, alcohol drinking status, work activities, and recreational activities.

The bold values were considered statistically significant.

TABLE 4 Association of cognitive function and depression scores with nocturia risk stratified by age.

Cognitive function and depression scores	Model	Age (60–69 years)		Age (70–80 ye	ars)
		OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value
Total word recall score	Non-adjusted	0.9588 (0.9431, 0.9748)	<0.000001	0.9862 (0.9700, 1.0025)	0.09746
	Adjust I	0.9785 (0.9596, 0.9978)	0.029319	0.9983 (0.9800, 1.0168)	0.85313
	Adjust II	0.9787 (0.9589, 0.9989)	0.039188	1.0007 (0.9812, 1.0205)	0.94732
Animal fluency score	Non-adjusted	0.9405 (0.9229, 0.9584)	<0.000001	0.9631 (0.9425, 0.9842)	0.000668
	Adjust I	0.9796 (0.9581, 1.0017)	0.069585	0.9834 (0.9598, 1.0076)	0.177499
	Adjust II	0.9845 (0.9618, 1.0077)	0.189148	0.9876 (0.9621, 1.0137)	0.347625
Digit symbol score	Non-adjusted	0.9727 (0.9668, 0.9787)	<0.000001	0.9804 (0.9735, 0.9873)	<0.000001
	Adjust I	0.9864 (0.9779, 0.9949)	0.001854	0.9877 (0.9789, 0.9966)	0.006738
	Adjust II	0.9879 (0.9788, 0.9970)	0.009101	0.9908 (0.9811, 1.0007)	0.069238
PHQ-9 score	Non-adjusted	1.1044 (1.0790, 1.1304)	<0.000001	1.0713 (1.0404, 1.1032)	0.000004
	Adjust I	1.0874 (1.0593, 1.1161)	<0.000001	1.0726 (1.0388, 1.1076)	0.000019
	Adjust II	1.0775 (1.0486, 1.1073)	<0.000001	1.0678 (1.0324, 1.1044)	0.000139

Model I was adjusted for male/female, age, race, education level, marital status, and poverty-to-income ratio.

Model II was adjusted for male/female, age, race, education level, marital status, and poverty-to-income ratio, body mass index, hypertension, diabetes, smoking status, alcohol drinking status, work activities, and recreational activities.



# TABLE 5 Association of cognitive function scores/PHQ-9 score with nocturia risk according to threshold values in females.

Variable	Odds ratio (95% confidence interval)	<i>p</i> -Value				
Total word	Total word recall score					
<30	1.0162 (0.9911, 1.0419)	0.2073				
>30	0.8602 (0.7964, 0.9291)	0.0001				
PHQ-9 score						
<1	1.4786 (1.1003, 1.9869)	0.0095				
>1	1.0388 (1.0066, 1.0720)	0.0178				

The bold values were considered statistically significant.

# 3.2 Correlation between nocturia, depression, and cognitive function

Multiple regression analysis revealed that TWRS, AFS, DSS, and PHQ-9 scores were significantly associated with the risk of nocturia. In the unadjusted model, higher cognitive function scores (TWRS, AFS, and DSS) were associated with a lower risk of nocturia, and higher PHQ-9 scores were linked with a higher risk of nocturia. After adjusting for variables, the association of DSS and PHQ-9 scores with the risk of depression remained significant (Table 2).

Restricted cubic spline curve showed that TWRS, and PHQ-9 scores had non-linear relationships with the risk of nocturia

(*p* for non-linear < 0.05). AFS and DSS were linearly associated with nocturia risk (*p* for non-linear > 0.05). And the risk of nocturia decreased by ~1% for every one-point increase in DSS (Figure 2). There was no significant association between AFS and nocturia risk.

# TABLE 6 Association of PHQ-9 score with nocturia risk according to threshold values in males.

Variable	Odds ratio (95% confidence interval)	p-Value
PHQ-9 scor	re	
<2	1.3854 (1.1901, 1.6126)	<0.0001
>2	1.0507 (1.0087, 1.0945)	0.0175
The bold values we	ere considered statistically significant.	

The association of TWRS, AFS, DSS, and PHQ-9 scores with nocturia risk stratified by male/female was shown in Table 3. The results showed that the associations were significant in

TABLE 7 Association of cognitive function scores with nocturia risk according to threshold values in 60-69 years.

Variable	Odds ratio (95% confidence interval)	<i>p</i> -Value				
Total word recall score						
<34	0.9927 (0.9709, 1.0151)	0.522				
>34	0.6675 (0.5163, 0.8630)	0.002				
Digit symbol score						
<67	0.9919 (0.9814, 1.0025)	0.132				
>67	0.9612 (0.9251, 0.9988)	0.0431				
The hold values were considered statistically significant						



# TABLE 8 Association of PHQ-9 score with nocturia risk according to threshold values in 70-80 years.

Variable	Odds ratio (95% confidence interval)	<i>p</i> -Value			
PHQ-9 score					
<1	2.0936 (1.5695, 2.7927)	<0.0001			
>1	1.0193 (0.9839, 1.0559)	0.2898			

The bold values were considered statistically significant.

the unadjusted model. In the adjusted models, PHQ-9 scores were positively significantly associated with the risk of nocturia in both males and females. There was a significant correlation between AFS, DSS, and the risk of nocturia in females (p < 0.05); specifically, lower scores were associated with a higher risk of nocturia. In contrast, no significant correlation was observed in males.

Subgroup analysis of age showed that the adjusted TWRS, DSS and PHQ-9 Score were significantly correlated with the risk of



(\*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001).

nocturia in the 60–69 years group (p < 0.05). Only the PHQ-9 Score was significantly correlated with the risk of nocturia in the 70–80 years group (p < 0.05, Table 4).

The relationships of cognitive function (TWRS, AFS, and DSS) with nocturia risk were linear in males (p for non-linear > 0.05). In females, TWRS, and PHQ-9 scores were non-linearly correlated with the risk of nocturia, while DSS and AFS were linearly associated with the risk of nocturia (Figure 3). For every 1-point increase in DSS and AFS in women, the risk of nocturia was reduced by  $\sim 2.8$  and 1.4%, respectively (p < 0.05). TWRS according to threshold values affected the risk of nocturia in females. TWRS >30 decreased the risk of nocturia by  $\sim 14\%$ (Table 5). PHQ-9 scores at thresholds of 2 for men and 1 for women indicate a significant association with nocturia. Specifically, when PHQ-9 scores are below these thresholds (i.e., below two for men and below one for women), the risk of nocturia increases by 38% in men and 48% in women, respectively. Conversely, when PHQ-9 scores exceed the respective thresholds, the risk of nocturia increases by 5% in men and 4% in women (Tables 5, 6).

There was a linear relationship between AFS and nocturia risk in different age groups (Figure 4). TWRS, and DSS were non-linear correlated with the risk of nocturia in 60–69 years group. When TWRS and DSS were > 34 and 67, the risk of nocturia was increased by 33 and 4%, respectively (Table 7). The PHQ-9 Score in the 70– 80 years group showed a non-linear relationship with the risk of nocturia. When the PHQ-9 Score was <1, the risk of nocturia increased by 109% (Table 8).

## 3.3 Analysis of mediating effects

We assessed the mediating effects of nutritional indexes on the relationship between nocturia, depression, and cognitive function. A bias-corrected bootstrap analysis at a 95% confidence interval based on 5,000 bootstrapped resamples was performed using PROCESS version 4.0, which did not rely on the assumption of normal distribution (31).

The previous results showed the signification correlation between nutritional indices (ALB, HGB) and nocturia (OR = -0.34, SE = 0.133, p = 0.01; OR = -0.085, SE = 0.032, p < 0.01). To further explore the mechanisms between cognitive function, depression and nocturia risk, we analyzed the mediating effects of ALB and HGB on these correlations.

Figure 5 showed that the direct effect of AFS on the risk of nocturia was -0.005327 (p = 0.006), the mediating effect of HGB was -0.000484 (p = 0.0068) and the mediating effect accounted for 8.11% (p = 0.0088). Meanwhile, HGB had a partial mediating effect on the correlation of DSS with nocturia risk, accounting for 11.02%. However, the mediating effect of HGB on the correlation of PHQ-9, DWRS with nocturia was not significant.

Similarly, ALB had a partial mediating effect on the correlation of AFS, DSS and PHQ-9 scores with nocturia risk in participants, accounting for 1.52, 1.50, and 2.6%, respectively. However, ALB did not mediate the association of DWRS with nocturia risk (Figure 5).

Subgroup analyses of male/female and age were used to study the stability and specificity of mediating effects. Subgroup analysis of male/female showed that HGB only played a partial mediating role in the correlation between AFS and nocturia in women, accounting for 6.60% (p = 0.026). Meanwhile, HGB only played a partial mediating role in the correlation between male PHQ-9 Score and nocturia, accounting for 4.07% (p = 0.02). HGB played a partial mediating role in the correlation between male and female DSS and nocturia, accounting for 13.4 and 6.81%, respectively (Table 5). ALB only partially mediated the correlation between AFS, DSS, PHQ-9 Score and nocturia risk in women, accounting for 5.00, 4.39 and 4.62%, respectively (Tables 9–12).

Age subgroup analysis showed that HGB had a direct effect of -0.002283 (p = 0.0284) and a mediating effect of -0.000647(p < 2e-16) in the correlation between DSS and nocturia risk in the 70–80 years group, accounting for 21.5% (p = 0.0052, Table 7). Similarly, albumin played a partial mediating role in the correlation between DSS and diabetes risk in the 70–80 years group, accounting for 8.07% (p = 0.041, Table 8). These results indicate that the correlation of AFS, DSS, and PHQ-9 scores with nocturia risk may be mediated by nutritional status (Tables 13–16).

### 3.4 Sensitivity analysis

Cognitive impairment frequently co-occurs with nocturia. Consequently, the relationship between cognitive function and nocturia in individuals without cognitive impairment was examined to evaluate the sensitivity of the study. The findings of the sensitivity analysis revealed a significant correlation between cognitive function in cognitively unimpaired individuals and the risk of nocturia (Supplementary Table S1), aligning with the aforementioned results.

# 4 Discussion

Nocturia was a significant public health problem worldwide. Nocturia was associated with increased all-cause mortality, poor sleep, depression, increased risk of falls and fractures, and reduced quality of life, and the multifactorial nature of the condition complicated its diagnosis and treatment (32). Lower urinary tract symptoms, benign prostatic hyperplasia, hypertension, diabetes, and sleep apnea are risk factors for nocturia (33-35). Although age, comorbidities, and sleep disturbances are widely recognized as common risk factors for nocturia and cognitive dysfunction, research exploring the relationship between nocturia and cognitive dysfunction remains relatively limited, particularly when compared to studies on other lower urinary tract diseases and symptoms (4, 36, 37). A meta-analysis showed that the prevalence of nocturia in older adults with cognitive impairment ranged from 45.8 to 61% (4). The regulation of urethral sphincter, urethra and bladder by neural network controls urine storage and urination (38-41). Among them, the pontine micturition center (PMC) mediated spino-bubo-spinal reflex was the basis of active urination control, and periaqueductal gray (PAG) was the switch to induce urination (42). The function of urination was regulated by PMC, PAG and prefrontal lobe coordination (41-43). The forebrain mediated attention, working memory and executive function through acetylcholine (44). These findings suggested that depression and CI were associated with

Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
Hemoglobin	DWRS				
	ACME (control)	-0.000307	-0.000882	0	0.17
	ACME (treated)	-0.000308	-0.000882	0	0.17
	ADE (control)	-0.00122	-0.005905	0	0.62
	ADE (treated)	-0.00122	-0.005907	0	0.62
	Total effect	-0.001527	-0.006308	0	0.54
	Prop. mediated (control)	0.071636	-1.455422	1.95	0.6
	Prop. mediated (treated)	0.071845	-1.455558	1.95	0.6
	ACME (average)	-0.000308	-0.000882	0	0.17
	ADE (average)	-0.00122	-0.005906	0	0.62
	Prop. mediated (average)	0.07174	-1.45549	1.95	0.6
	AFS				
	ACME (control)	-0.000197	-0.000779	0	0.41
	ACME (treated)	-0.000197	-0.00078	0	0.41
	ADE (control)	-0.002546	-0.007949	0	0.38
	ADE (treated)	-0.002546	-0.007951	0	0.38
	Total effect	-0.002743	-0.008235	0	0.34
	Prop. mediated (control)	0.041829	-0.759598	1	0.58
	Prop. mediated (treated)	0.041894	-0.760016	1	0.58
	ACME (average)	-0.000197	-0.00078	0	0.41
	ADE (average)	-0.002546	-0.00795	0	0.38
	Prop. mediated (average)	0.041861	-0.759807	1	0.58
	DSS				
	ACME (control)	-0.00043	-0.000832	0	0.0068
	ACME (treated)	-0.000431	-0.000833	0	0.0068
	ADE (control)	-0.002661	-0.004536	0	0.0172
	ADE (treated)	-0.002662	-0.004538	0	0.0172
	Total effect	-0.003092	-0.004907	0	0.0048
	Prop. mediated (control)	0.134157	0.031391	0.49	0.0116
	Prop. mediated (treated)	0.13438	0.031504	0.49	0.0116
	ACME (average)	-0.000431	-0.000833	0	0.0068
	ADE (average)	-0.002662	-0.004536	0	0.0172
	Prop. mediated (average)	0.134268	0.031438	0.49	0.0116
	PHQ-9 score				
	ACME (control)	0.00079	0.0000932	0	0.02
	ACME (treated)	0.000797	0.0000938	0	0.02
	ADE (control)	0.0177	0.00904	0.03	<2e-16
	ADE (treated)	0.0177	0.00904	0.03	<2e-16
	Total effect	0.0185	0.00991	0.03	<2e-16
	Prop. mediated (control)	0.0405	0.00503	0.12	0.02
	Prop. mediated (treated)	0.0408	0.00508	0.12	0.02
	ACME (average)	0.000793	0.0000935	0	0.02
	ADE (average)	0.0177	0.00904	0.03	<2e-16
	Prop. mediated (average)	0.0407	0.00506	0.12	0.02

TABLE 9 Mediating effects of hemoglobin on the relationship of cognitive function and depression scores with the risk of nocturia in males.

Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
Hemoglobin	DWRS				
	ACME (control)	-0.00014	-0.000569	0	0.41
	ACME (treated)	-0.00014	-0.00057	0	0.41
	ADE (control)	-0.00329	-0.007351	0	0.15
	ADE (treated)	-0.00329	-0.007352	0	0.15
	Total effect	-0.00343	-0.007494	0	0.13
	Prop. mediated (control)	0.030897	-0.26367	0.42	0.47
	Prop. mediated (treated)	0.031042	-0.263724	0.42	0.47
	ACME (average)	-0.00014	-0.000569	0	0.41
	ADE (average)	-0.00329	-0.007352	0	0.15
	Prop. mediated (average)	0.03097	-0.263697	0.42	0.47
	AFS				
	ACME (control)	-0.000608	-0.00135	0	0.024
	ACME (treated)	-0.000612	-0.001358	0	0.024
	ADE (control)	-0.00817	-0.01294	0	0.0044
	ADE (treated)	-0.008173	-0.012948	0	0.0044
	Total effect	-0.008782	-0.013552	0	0.002
	Prop. mediated (control)	0.065739	0.006971	0.25	0.026
	Prop. mediated (treated)	0.066224	0.007078	0.25	0.026
	ACME (average)	-0.00061	-0.001356	0	0.024
	ADE (average)	-0.008171	-0.012945	0	0.0044
	Prop. mediated (average)	0.065981	0.007025	0.25	0.026
	DSS				
	ACME (control)	-0.000263	-0.000564	0	0.0364
	ACME (treated)	-0.000264	-0.000565	0	0.0364
	ADE (control)	-0.00348	-0.004887	0	0.0016
	ADE (treated)	-0.003481	-0.004888	0	0.0016
	Total effect	-0.003744	-0.005123	0	<2e-16
	Prop. mediated (control)	0.068026	0.003502	0.19	0.0364
	Prop. mediated (treated)	0.06824	0.003522	0.19	0.0364
	ACME (average)	-0.000264	-0.000564	0	0.0364
	ADE (average)	-0.003481	-0.004888	0	0.0016
	Prop. mediated (average)	0.068133	0.003512	0.19	0.0364
	PHQ-9 score				
	ACME (control)	-3.63E-05	-5.97E-04	0	0.876
	ACME (treated)	-3.66E-05	-6.01E-04	0	0.876
	ADE (control)	1.18E-02	2.23E-03	0.02	0.016
	ADE (treated)	1.18E-02	2.23E-03	0.02	0.016
	Total effect	1.17E-02	2.16E-03	0.02	0.015
	Prop. mediated (control)	-2.71E-03	-8.31E-02	0.07	0.88
	Prop. mediated (treated)	-2.75E-03	-8.32E-02	0.07	0.88
	ACME (average)	-3.65E-05	-5.99E-04	0	0.876
	ADE (average)	1.18E-02	2.23E-03	0.02	0.016
	Prop. mediated (average)	-2.73E-03	-8.32E-02	0.07	0.88

TABLE 10 Mediating effects of hemoglobin on the relationship of cognitive function and depression scores with the risk of nocturia in females.

Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
Albumin	DWRS				
	ACME (control)	-0.00019	-0.000655	0	0.26
	ACME (treated)	-0.00019	-0.000655	0	0.26
	ADE (control)	-0.001562	-0.006318	0	0.55
	ADE (treated)	-0.001562	-0.006319	0	0.55
	Total effect	-0.001752	-0.006464	0	0.5
	Prop. mediated (control)	0.036356	-0.886118	1.08	0.61
	Prop. mediated (treated)	0.036449	-0.886158	1.08	0.61
	ACME (average)	-0.00019	-0.000655	0	0.26
	ADE (average)	-0.001562	-0.006319	0	0.55
	Prop. mediated (average)	0.036402	-0.886138	1.08	0.61
	AFS				
	ACME (control)	-0.000275	-0.000804	0	0.13
	ACME (treated)	-0.000275	-0.000805	0	0.13
	ADE (control)	-0.002345	-0.007756	0	0.4
	ADE (treated)	-0.002345	-0.007755	0	0.4
	Total effect	-0.00262	-0.007981	0	0.34
	Prop. mediated (control)	0.056633	-1.033905	1.21	0.43
	Prop. mediated (treated)	0.056788	-1.033961	1.21	0.43
	ACME (average)	-0.000275	-0.000805	0	0.13
	ADE (average)	-0.002345	-0.007755	0	0.4
	Prop. mediated (average)	0.056711	-1.033933	1.21	0.43
	DSS				
	ACME (control)	-0.00012	-0.000373	0	0.164
	ACME (treated)	-0.00012	-0.000373	0	0.164
	ADE (control)	-0.002628	-0.004587	0	0.027
	ADE (treated)	-0.002628	-0.004586	0	0.027
	Total effect	-0.002748	-0.004688	0	0.02
	Prop. mediated (control)	0.038202	-0.026364	0.23	0.181
	Prop. mediated (treated)	0.038239	-0.026394	0.23	0.181
	ACME (average)	-0.00012	-0.000373	0	0.164
	ADE (average)	-0.002628	-0.004586	0	0.027
	Prop. mediated (average)	0.038221	-0.026379	0.23	0.181
	PHQ-9 score				
	ACME (control)	0.00038	-0.000338	0	0.3
	ACME (treated)	0.000384	-0.000341	0	0.3
	ADE (control)	0.01864	0.00989	0.03	<2e-16
	ADE (treated)	0.018644	0.009891	0.03	<2e-16
	Total effect	0.019024	0.010283	0.03	<2e-16
	Prop. mediated (control)	0.017197	-0.019335	0.08	0.3
	Prop. mediated (treated)	0.017378	-0.019467	0.08	0.3
	ACME (average)	0.000382	-0.000339	0	0.3
	ADE (average)	0.018642	0.009891	0.03	<2e-16
	Prop. mediated (average)	0.017287	-0.019401	0.08	0.3

### TABLE 11 Mediating effects of albumin on the relationship of cognitive function and depression scores with the risk of nocturia in males.

<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
ACME (control)0.003910.0039200.023ACME (control)0.003740-0.0074600.00.0414ADE (control)0.0037400.0077400.00.015Progn mediated (control)-0.0037400.4347410.020.012Progn mediated (control)-0.0037400.4347410.020.012ADE (correge)0.0037300.4347410.020.023ADE (correge)0.0037300.424810.020.023ADE (correge)0.0037300.010700.010.023ADE (correge)0.0037300.010700.00.023ADE (correge)0.0037300.010700.00.03341ADE (correge)0.003700.010700.00.03541ADE (correge)0.003700.010700.00.00341ADE (correge)0.015700.01070.003410.00341ADE (correge)0.015700.01070.003410.00344ADE (correge)-0.015700.02140.003440.00344ADE (correge)-0.005700.002140.02040.00344ADE (correge)-0.005700.002140.02040.00344ADE (correge)-0.005700.002140.00240.00244ADE (correge)-0.005700.002140.00240.00244ADE (correge)-0.005700.002140.00240.00244ADE (correge)-0.005700.002140.00240.00244ADE (correge	Albumin	DWRS				
AXME (protac)0.000820-0.00082000.0144ADE (tracial)0.003840.00747600.141Data (arca)0.0037400.0078800.00.161Prop. madiate (control)0.0867310.4247410.020.128Prop. madiate (control)0.08679310.4247410.020.128Prop. madiate (control)0.08679310.4025020.020.028AXME (varcage)0.08679310.4025020.020.028AXME (varcage)0.0879310.4025020.020.028AXE (varcage)0.0879310.4025020.020.028AXE (varcage)0.0203510.4025020.020.0056AXE (varcage)00.004570.0129210.000.0056AXE (varcage)0.02054-0.0129210.000.0056AXE (varcage)0.02054-0.0129210.000.0056AXE (varcage)0.02054-0.0129210.020.0056AXE (varcage)0.02054-0.0129210.020.0056AXE (varcage)0.02054-0.0129210.020.0056AXE (varcage)0.02054-0.0129210.020.0056AXE (varcage)0.02054-0.0129210.020.0268AXE (varcage)0.02054-0.022450.020.0268AXE (varcage)0.02054-0.020540.020.0268AXE (varcage)0.02054-0.020540.02680.0268AXE (varcage)0.02354 <td></td> <td>ACME (control)</td> <td>-0.000391</td> <td>-0.00096</td> <td>0</td> <td>0.028</td>		ACME (control)	-0.000391	-0.00096	0	0.028
ADE (control)0.003340.0074900.141ADB (control)0.003740.007400.050.141Prop. nodited (control)0.0087350.4247410.620.128Prop. nodited (control)0.0087310.425050.620.128ADE (serage)0.003330.07780.020.02ADE (serage)0.003330.07780.020.128ADE (serage)0.003330.07780.020.0384ADE (serage)0.004550.010740.00.0384ADE (serage)0.00457-0.010740.00.0384ADE (serage)0.00457-0.010740.00.0384ADE (serage)0.004540.010740.00.0384ADE (serage)0.004540.0129230.00.0054ADE (serage)0.004540.0129240.00.0054ADE (serage)0.040840.0129240.00.0054ADE (serage)0.040560.0129240.00.0054ADE (serage)0.040560.0129240.00.0054ADE (serage)0.001760.021240.00.0054ADE (serage)0.001760.021240.00.0264ADE (serage)0.001760.021240.00.0264ADE (serage)0.001760.021240.00.0264ADE (serage)0.001760.021240.00.0264ADE (serage)0.001760.00176		ACME (treated)	-0.000392	-0.000962	0	0.028
ADE (mansal)0.0033440.00729400.014Todal (control)0.0007240.0072860.0.20.0.28Prop. mediated (matted)0.00073300.4024020.0.220.0.22ADE (morage)0.0003810.0007480.0.20.0.22ADE (morage)0.0008300.4074780.00.0.22Prop. mediated (marge)0.0008300.4074780.00.0.22ADE (morage)0.0008300.401840.0.20.0.22ADE (morage)0.0008300.401840.0.20.0.054ADE (morage)0.0008470.001740.00.00341ADE (morage)0.0008470.0128210.00.0054ADE (morage)0.0009470.0128210.00.0054ADE (morage)0.0019740.0128240.00.0034ADE (morage)0.001974-0.0128240.00.00354ADE (morage)0.001974-0.011770.00.00364ADE (morage)0.001976-0.001770.00.00364ADE (morage)0.001976-0.001770.00.00364ADE (morage)0.001978-0.001770.00.0026ADE (morage)0.001978-0.001770.00.0026ADE (morage)0.001797-0.0017950.00.0026ADE (morage)0.001797-0.0017970.00.0026ADE (morage)0.001797-0.0017970.00.0026ADE (morage) <td>ADE (control)</td> <td>-0.003383</td> <td>-0.007476</td> <td>0</td> <td>0.144</td>		ADE (control)	-0.003383	-0.007476	0	0.144
Iodudfick0.093740.0738800.013Prop. mediated (cread)0.08679310.4247410.0520.021Prop. mediated (cread)0.06099310.0009420.020.023ACME (merage)0.0033830.0074780.0120.0124Prop. mediated (areage)0.003910.0009710.0120.0124AS0.0010740.010140.003440.0120.0384ACME (notrol)0.0019770.0107900.00344ACME (notrol)0.001977-0.0122340.000540.00054ADE (notrol)0.001977-0.0123240.000240.00024ADE (notrol)0.009541-0.0119770.00.0024ADE (notrol)0.0095410.0023540.00.0056Frop. mediated (control)0.00954-0.01197410.00.00344ADE (notrol)0.00954-0.01197410.00.00344ADE (notrol)0.00954-0.01197410.00.0056Prop. mediated (corrug)0.00954-0.01197410.00.0056ADE (notrol)-0.00176-0.0017610.00.0026ADE (notrol)-0.00176-0.0017610.00.0026ADE (notrol)-0.00176-0.0017610.00.0026ADE (notrol)-0.00176-0.0017610.00.0026ADE (notrol)-0.00176-0.0017610.00.0026ADE (notrol)-0.00176-0.0017610.00.0266ADE (notro		ADE (treated)	-0.003384	-0.007479	0	0.144
Prog.mediand (created)0.089735-0.4247410.020.0124Prog.mediand (created)0.000931-0.4259250.02.20.02.3ACME (overage)-0.000334-0.0007630.00.014Prog.mediand (overage)0.05833-0.428830.02.20.012.3ATE-0.000354-0.0017630.020.00054ACME (control)00001700.010.000540.00054ACME (control)00001700.010.000540.00054ACME (control)00001740.012230.000540.00054ACME (control)0.0001700.0022450.020.00054ATE (affection)0.001510.0022450.020.00054ADE (overage)0.0010700.002240.00560.00054ADE (overage)0.0010700.002240.005640.00054ADE (overage)0.0010700.001240.002540.00564ADE (overage)0.0010710.001740.002540.00254ADE (overage)0.0010710.001740.001640.00264ADE (overage)0.001610.001640.002640.00264ADE (overage)0.001610.001740.001740.00264ADE (overage)0.001610.001640.001640.00264ADE (overage)0.001630.001640.001640.00264ADE (overage)0.001630.001640.001640.00264ADE (overage)0.001640.001640.002640.00164ADE (overage		Total effect	-0.003774	-0.007888	0	0.105
Peq.netande (restrict)0.003710.423230.020.00373ACME (orenge)0.0037330.4007430.00.02Prop. medica (dresc)0.0037330.4007430.020.03Prop. medica (dresc)0.4007530.401740.0030.0314ACME (orard)0.4007030.4017430.0030.00354ADE (orard)0.4007970.4017230.000.00214ADE (orard)0.4003410.4012320.00.00214ADE (orard)0.4003410.4012340.00.00214ADE (orard)0.4003410.4012340.00.00214ADE (orard)0.4003410.4012340.00.00214ADE (orard)0.4003410.4012340.00.0014ADE (orard)0.4003410.401240.00140.0014ADE (orard)0.400790.012340.00.0014ADE (orard)0.400790.01240.00150.0015ADE (orard)0.400790.01240.00240.0024ADE (orard)0.400790.01240.00150.0015ADE (orard)0.400790.01250.00150.0015ADE (orard)0.400790.01240.00240.0024ADE (orard)0.401410.401410.00240.0024ADE (orard)0.401410.001410.00240.0014ADE (orard)0.401410.001410.001410.0024ADE (orard)0.401410.001410.00140.0014ADE (o		Prop. mediated (control)	0.087735	-0.424741	0.82	0.128
ACME (nerge)0.003930.00374300.0124ADE (nerge)0.003330.0072400.014ATS0.004500.001740.0-0.00384ACME (nerge)0.00457-0.001740.00.00384ADE (nerge)0.0057-0.001740.00.00164ADE (nerge)0.0057-0.001740.00.00214ADE (nerge)0.0054-0.0012740.00.00214ADE (nerge)-0.00154-0.001240.00.00124ADE (nerge)-0.00164-0.0012740.00.00144ADE (nerge)-0.00164-0.0012740.00.00144ADE (nerge)-0.00164-0.001740.00.00144ADE (nerge)-0.00164-0.001740.00.00144ADE (nerge)-0.00174-0.001740.00.00144ADE (nerge)-0.00174-0.001740.00.00144ADE (nerge)-0.00174-0.001740.00.00144ADE (nerge)-0.00174-0.001740.00.00144ADE (nerge)-0.00174-0.001740.0ADE (nerge)-0.00174-0.001740.00.00144ADE (nerge)-0.00174-0.001740.00.00144ADE (nerge)-0.00174-0.001740.00.0ADE (nerge)-0.00174-0.001740.00.0ADE (nerge)-0.00174-0.001740.00.0ADE (nerge)-0.00174-0.001740.0		Prop. mediated (treated)	0.087931	-0.425025	0.82	0.128
ADE (nerroge)0.0033330.007783000.12.8Prop. mediate (nerroge)0.0583330.4248830.08.20.0128ASM0.00107500.00107400.03844ACME (nerol)0.0017970.0012920.00.00354ACME (nerol)0.0017970.0129270.00.00264ADE (norto)0.0017970.0129270.00.00264ADE (norto)0.00174-0.0129270.00.00264Anad (nerol)0.091990.0022450.020.00164Andar (nerol)0.0017600.001740.020.00561ADE (nerol)0.001740.0017240.00.00245ADE (nerol)-0.00176-0.001740.00.00245ADE (nerol)0.000176-0.001740.00.00245ADE (nerol)-0.00176-0.001740.001740.00174ADE (nerol)-0.00175-0.001750.00.0014ADE (nerol)-0.00174-0.001750.00.0014ADE (nerol)-0.00175-0.001750.00.0014ADE (nerol)-0.00175-0.001750.00.00245ADE (nerol)-0.00175-0.001750.00.00257ADE (nerol)-0.00175-0.001750.00.00257ADE (nerol)-0.00175-0.001750.00.00257ADE (nerol)-0.00175-0.001750.00.00257ADE (nerol)-0.00175-0.001670.00.0025		ACME (average)	-0.000391	-0.000962	0	0.028
Prop.mediated (average)0.087833-0.4248330.620.123AIS0.001750.001750.00.0384ACME (cantrol)-0.0007500.00.0384ACME (cantrol)-0.0007700.00.0384ADE (cantrol)-0.0017970.00.0016ADE (cantrol)-0.0018740.0129270.00.0024Prop.mediated (cantrol)0.0018100.0022350.00.0016Prop.mediated (cantrol)0.0016100.0021350.002140.00161Prop.mediated (cantrol)0.0016100.0022440.001610.00161ACME (carterg)0.0010700.0022440.001620.00056Prop.mediated (carterg)0.0001700.0022440.001620.00056Prop.mediated (carterg)0.0001700.0021400.0021400.00257ACME (carterg)0.0016700.0001500.001610.0021400.00257ACME (carterg)0.0016100.0001500.001610.001610.00161ACME (carterg)0.0016100.0001500.001610.002570.00161ACME (carterg)0.0015100.0001500.001610.002570.00161ACME (carterg)0.0015100.002570.0130.02254ACME (carterg)0.0015100.002570.0130.02254ACME (carterg)0.0015100.002570.01610.00258ACME (carterg)0.0015100.002570.01610.00258ACME (carterg)0.0161100.00257<		ADE (average)	-0.003383	-0.007478	0	0.144
AFSInterfactInterfactInterfactACME (control)-0.000570-0.0017030.00.00341ACME (tractard)-0.000770-0.0017030.0012010.000501ADE (control)-0.001970-0.0129200.001600.00121ADE (control)-0.001970-0.0012010.001210.00121Inderfact-0.001970-0.0012010.001210.00121Inderfact-0.001910-0.001210.001210.00121ADE (control)-0.00170-0.001240.01010.00121ADE (control)-0.00170-0.001240.01010.00121ADE (control)-0.00170-0.001700.0010.0014ADE (control)-0.00170-0.001700.0010.0014ADE (control)-0.00170-0.001700.0010.0014ADE (control)-0.00170-0.001700.0010.0014ADE (control)-0.00170-0.001700.0010.0014ADE (control)-0.00170-0.001700.010.0014ADE (control)-0.00170-0.001700.010.0014ADE (control)-0.00170-0.001700.010.0014ADE (control)-0.00170-0.001700.010.0021ADE (control)-0.00170-0.001700.010.0021ADE (control)-0.00170-0.001700.010.0021ADE (control)-0.00170-0.001700.010.0021ADE (control)-0.00170-0.00170		Prop. mediated (average)	0.087833	-0.424883	0.82	0.128
ACME (control)0.0004570.0017900.0.0384ACME (treated)0.000457-0.00179200.0.0356ADE (control)0.000970.0123270.00.00056ADE (treated)0.0084540.0133660.0.20.04084Prop. mediated (torated)0.0499990.0022150.0.20.04084ADE (treated)0.0501150.0022450.0.20.04084ADE (torateg)0.000576-0.010770.00.00564ADE (torateg)0.050070.012240.20.04084Drop. mediated (varage)0.050070.02140.20.00567Prop. mediated (varage)0.050070.001720.00.0258Drop. mediated (varage)0.050070.001700.00.0268Drop. mediated (varage)-0.000176-0.001700.00.0268Drop. mediated (varage)-0.000176-0.0001700.00.0004ADE (treated)-0.000176-0.0001700.00.0004Drop. mediated (varage)-0.000176-0.0001700.00.0004Drop. mediated (varage)0.002815-0.0001700.00.0004Prop. mediated (varage)-0.000176-0.0001700.00.0004Drop. mediated (varage)-0.000176-0.0001700.00.0004Drop. mediated (varage)-0.000176-0.0001700.00.0004Prop. mediated (varage)-0.000176-0.0001700.00.0028Drop. mediated (varage)-		AFS				
ACME (treated)0.0001970.010797000.00384ADE (control)0.0009970.0139230.00.00056ADE (treated)0.0084540.0132760.00.0024Prop. mediated (orotrol)0.0029900.0022550.20.00408Prop. mediated (treated)0.00501150.0022450.20.00384ACME (overage)0.0004560.001770.00.00384Prop. mediated (verage)0.005007-0.013240.00.00356Prop. mediated (verage)0.050007-0.013240.00.00365DS0.00176-0.0040300.00.0268DS0.000176-0.0040300.00.0268DS0.000176-0.0001760.00.0004ADE (control)0.000176-0.0001760.00.00268ADE (control)-0.000176-0.0001760.00.0004Total (ferca0.000176-0.0001760.00.0004Total (ferca0.000176-0.0001760.00.0004Total (ferca0.000176-0.0001760.00.0004Total (ferca0.000176-0.0001760.00.0004Total (ferca0.000176-0.0001760.00.0004Total (ferca-0.000176-0.0001760.00.0208ADE (rearde)0.04021-0.000176-0.0001760.010Total (ferca-0.000176-0.0001760.0100.0208ADE (rearde)0.00		ACME (control)	-0.000455	-0.001074	0	0.0384
ADE (control)0.0079970.01292300.00956ADE (trated)0.00840.0132670.00.0024Total effect0.0084540.0133660.20.0024Prop. mediated (control)0.0048990.0022550.20.04088Prop. mediated (treated)-0.001560.0010770.00.0354ADE (average)0.0019780.0102740.20.00488DS0.001760.002440.020.00488DS0.001760.0004550.00.00248ADE (control)0.001760.0004550.00.0268ADE (control)0.001760.0004550.000440.00044ADE (control)0.0031650.0031750.00.00268ADE (control)-0.003791-0.0031750.00.0268ADE (control)-0.003161-0.0005150.00.00268ADE (control)0.0440210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)0.049210.002880.130.0268ADE (control)10.45820.020.031 <t< td=""><td></td><td>ACME (treated)</td><td>-0.000457</td><td>-0.001079</td><td>0</td><td>0.0384</td></t<>		ACME (treated)	-0.000457	-0.001079	0	0.0384
ADE (reated)0.0080.01292700.00056Total effect0.0084540.01336600.00224Prop. mediated (treated)0.050150.0022450.0.20.04048Prop. mediated (treated)-0.0004560.0022460.20.04048ACME (average)-0.000956-0.0129240.00.00564DSS-0.0009760.002240.20.04048DSK-0.000176-0.0004300.00.0228ACME (control)-0.000176-0.00040300.0228ACME (control)-0.000176-0.0001760.00.0024DS (control)-0.003150.005170.00040.0004Do (control)-0.00315-0.001750.0-0.00176Do (control)-0.0031760.0130.02680.0004Do (control)-0.003150.002780.00040.0268Drop. mediated (control)0.048210.002780.130.0268ACME (average)-0.00176-0.0016500.0004Prop. mediated (verage)-0.00176-0.001660.00040.0028ACME (average)-0.00176-0.001650.00.0028ADE (average)-0.00176-0.001650.00.0028ADE (average)-0.00176-0.001760.00.0228Prop. mediated (control)0.040210.002810.0130.0228ADE (average)-0.00176-0.001760.00.0016Prop. mediated (control)0.04021 <td></td> <td>ADE (control)</td> <td>-0.007997</td> <td>-0.012923</td> <td>0</td> <td>0.0056</td>		ADE (control)	-0.007997	-0.012923	0	0.0056
Total effect0.0084540.013366000.0024Prop. mediated (control)0.0498990.0022350.20.0408Prop. mediated (treated)0.051150.0022450.20.0408ACME (average)0.0004560.0010700.020.0384ADE (average)0.0500070.0022400.0408Prop. mediated (average)0.0500070.002240.20.0408DSS0.001760.001700.020.0408ACME (control)0.0001760.0040300.0268ADE (control)0.0037160.00517500.0004Total effect0.0037910.00517500.0268ADE (treated)-0.003719-0.0051750.0130.0268Total effect0.003719-0.0051750.03.0268Prop. mediated (treated)0.0402110.002880.130.0268ADE (average)-0.003718-0.00517600.0268Prop. mediated (treated)0.0017610.002880.130.0268ADE (average)0.0402110.002880.130.0268ADE (average)0.041210.0028830.130.0268ADE (average)0.0419210.002880.130.0268ADE (average)0.0419213.992+0500.028ADE (average)0.0419213.992+0500.028ADE (control)5.63E+043.992+0500.028ADE (control)1.13E+02<		ADE (treated)	-0.008	-0.012927	0	0.0056
Prop. mediated (control)0.0498990.0022350.20.0408Prop. mediated (treated)0.0501150.0022450.20.0408ACNE (average)-0.00197000.03840.056Prop. mediated (average)0.050070.002240.20.05067DSS-0.0129240.20.20.05067DSK-0.001750.002240.20.0228ACME (control)-0.00176-0.0040300.0228ADE (treated)-0.00176-0.004050.00.0004DS-0.00176-0.00517500.0004ADE (treated)-0.003615-0.0051750-0.0004Dot (treated)0.0438210.0028780.130.0228ADE (treated)0.0418210.0028780.130.0268Prop. mediated (treated)0.00176-0.0017600.0004Prop. mediated (treated)0.00176-0.001780.00.0268ADE (average)0.0418210.0028780.130.0268ADE (average)0.00176-0.001760.00.0004Prop. mediated (treated)0.00176-0.001760.00.0028ADE (average)0.0139210.0028830.130.0268ADE (average)0.00176-0.001760.00.002ADE (average)5.55E-043.39E-0500.022ADE (control)5.55E-043.39E-050.020.031ADE (treated)1.07E-021.23E-030.0220.031 <td></td> <td>Total effect</td> <td>-0.008454</td> <td>-0.013366</td> <td>0</td> <td>0.0024</td>		Total effect	-0.008454	-0.013366	0	0.0024
Prop. mediated (treated)0.050150.0022450.20.0408ACME (average)-0.00056-0.0017700.03384ADE (average)0.050070.002240.00.0056Prop. mediated (average)0.050070.002240.20.0408DSS-0.00176-0.0001600.00.0268ACME (control)-0.000176-0.0001650.00.0268ACME (control)-0.00315-0.0051500.0004ADE (treated)-0.003615-0.0051700.00268Prop. mediated (control)0.0448210.002780.130.0268ACME (average)0.0449210.002780.130.0268Prop. mediated (netrol)0.0449210.002880.130.0268ADE (average)0.0449210.002880.130.0268ADE (average)0.049120.002810.03280.130.0268ADE (average)0.049210.002880.130.0268Prop. mediated (average)0.049210.002810.0310.0268ADE (average)0.049210.002810.030.028Prop. mediated (average)0.049210.002810.0280.130.028Prop. mediated (average)0.049210.002810.0280.130.028ADE (average)0.049210.002810.0280.130.028Prop. mediated (average)0.049210.002810.0280.0210.028ADE (average)1.07E-021.23E-03 <t< td=""><td></td><td>Prop. mediated (control)</td><td>0.049899</td><td>0.002235</td><td>0.2</td><td>0.0408</td></t<>		Prop. mediated (control)	0.049899	0.002235	0.2	0.0408
ACME (average)0.004560.00177100.0384ADE (average)-0.00798-0.01292400.0056Prop. mediated (average)0.0500070.002240.20.0408DSSACME (control)0.001760.0040300.0268ADE (control)0.0036150.00501500.0004ADE (control)0.0036150.00517500.0004Total effect0.003710-0.0051750-2c-16Prop. mediated (control)0.0448210.002880.130.0268ADE (verage)0.001760.0031500-2c-16Prop. mediated (control)0.0449210.002880.130.0268ADE (average)0.0449210.0028830.130.0268ADE (average)0.0439210.0028130.130.0268Prop. mediated (average)0.0439210.0028130.130.0268PriQ-9 scoreADE (control)5.59E-043.99E-0500.028ADE (control)1.07E-021.23E-030.020.031ADE (control)1.07E-021.23E-030.020.031ADE (control)1.13E-0250E-040.240.052ADE (average)1.13E-0250E-040.240.052ADE (average)1.61E-0250E-040.240.052ADE (average)1.61E-0250E-040.240.052		Prop. mediated (treated)	0.050115	0.002245	0.2	0.0408
ADE (average)0.0079980.01292400Prop. mediated (average)0.0500070.002240.20.04008DSS </td <td></td> <td>ACME (average)</td> <td>-0.000456</td> <td>-0.001077</td> <td>0</td> <td>0.0384</td>		ACME (average)	-0.000456	-0.001077	0	0.0384
Prop. mediated (average)0.050070.002240.20.0408DSS0.0001760.00040300.0268ACME (control)0.0001760.00040500.0268ADE (control)0.0036150.00501500.0004ADE (treated)0.003710-0.00501700.0004ADE (treated)0.0037910.0051750<2e-16		ADE (average)	-0.007998	-0.012924	0	0.0056
DSSImage: state s		Prop. mediated (average)	0.050007	0.00224	0.2	0.0408
ACME (control)0.001760.0040300.0268ACME (treated)0.0036150.00501500.0004ADE (control)0.0036150.00501700.0004ADE (treated)0.0037910.0051750<22-e-16		DSS				
ACME (treated)0.001760.0040500.0268ADE (control)0.0036150.00501700.0004ADE (treated)0.0036150.005176002.0-16Total effect0.003710-0.0028780.130.0268Prop. mediated (treated)0.0440210.0028880.130.0268ACME (average)0.001760.000106000.0268ADE (average)0.0036150.00016600.00268Prop. mediated (average)0.0439210.0028830.130.0268Prop. mediated (average)0.0439210.0028830.130.0268Prop. mediated (average)0.0439210.0028330.130.0268Prop. mediated (average)0.0439210.0028330.130.0268Prop. mediated (average)0.0439213.99E-0500.028ACME (control)5.59E-043.99E-0500.028ADE (control)1.07E-021.23E-030.020.031ADE (control)1.07E-021.23E-030.020.052ADE (treated)1.13E-021.89E-030.020.052Prop. mediated (treated)4.66E-02-5.07E-040.240.052ADE (average)5.61E-044.02E-0500.028ADE (average)5.61E-044.02E-0500.028ADE (average)5.61E-041.23E-030.020.031ADE (average)5.61E-044.02E-0500.028 <t< td=""><td></td><td>ACME (control)</td><td>-0.000176</td><td>-0.000403</td><td>0</td><td>0.0268</td></t<>		ACME (control)	-0.000176	-0.000403	0	0.0268
ADE (control)0.0036150.00501500.0004ADE (treated)0.0036150.005017000.0004Total effect0.0037910.0051750<-2c-16		ACME (treated)	-0.000176	-0.000405	0	0.0268
ADE (treated)0.0036150.00517000.0004Total effect0.0037910.00517500<-2e-16		ADE (control)	-0.003615	-0.005015	0	0.0004
Total effect0.0037910.0051750<-<2e16Prop. mediated (control)0.0438210.0028780.0130.0268Prop. mediated (treated)0.0440210.0028880.130.0268ACME (average)0.0001760.000405000.00048ADE (average)0.0439210.0028830.130.0268Prop. mediated (average)0.0439210.0028830.130.0268PHQ-9 scoreACME (control)5.59E-043.99E-0500.028ACME (treated)5.59E-043.99E-0500.028ACME (treated)1.07E-021.23E-030.020.031ADE (control)1.07E-021.23E-030.020.031ADE (reated)1.13E-021.89E-030.0240.052Prop. mediated (control)4.66E-02-5.07E-040.240.052ACME (average)5.51E-044.02E-0500.028ADE (average)1.07E-021.23E-030.0240.052Prop. mediated (control)4.66E-02-5.08E-040.240.052ACME (average)5.51E-044.02E-0500.028ADE (average)5.61E-044.02E-0500.028ADE (average)5.61E-044.02E-0500.028ADE (average)1.07E-021.23E-030.020.031ADE (average)6.61E-044.02E-0500.028ADE (average)1.07E-021.23E-03		ADE (treated)	-0.003615	-0.005017	0	0.0004
Prop. mediated (control)0.0438210.0028780.130.0268Prop. mediated (treated)0.0440210.0028880.130.0268ACME (average)-0.000176-0.000405000.0268ADE (average)0.0439210.0028830.130.00268Prop. mediated (average)0.0439210.0028830.130.0268PHQ-9 score		Total effect	-0.003791	-0.005175	0	<2e-16
Prop. mediated (treated)0.0440210.0028880.130.0268ACME (average)-0.000176-0.00040500.00268ADE (average)-0.003615-0.00501600.0004Prop. mediated (average)0.0439210.0028830.130.0268PHQ-9 scoreACME (control)5.59E-043.99E-0500.028ACME (treated)5.59E-043.99E-0500.028ACME (treated)1.07E-021.23E-030.020.031ADE (treated)1.07E-021.23E-030.020.024Prop. mediated (control)4.60E-02-5.07E-040.240.052Prop. mediated (treated)4.64E-02-5.08E-040.240.052ACME (average)1.07E-021.23E-030.020.028Prop. mediated (reated)4.64E-02-5.08E-040.240.052ACME (average)1.07E-021.23E-030.020.028ADE (average)4.64E-02-5.08E-040.240.052ADE (average)1.07E-021.23E-030.020.031ADE (average)1.07E-021.23E-030.020.031ADE (average)1.07E-021.23E-030.020.031ADE (average)1.07E-021.23E-030.020.031ADE (average)1.07E-021.23E-030.020.031ADE (average)1.07E-021.23E-030.020.031ADE (average)1.07E-021.23E-03 <td></td> <td>Prop. mediated (control)</td> <td>0.043821</td> <td>0.002878</td> <td>0.13</td> <td>0.0268</td>		Prop. mediated (control)	0.043821	0.002878	0.13	0.0268
ACME (average)0.001760.0040500.0268ADE (average)0.0036150.005016000.0004Prop. mediated (average)0.0439210.0028830.130.0268PHQ-9 scoreACME (control)5.59E-043.99E-0500.028ACME (treated)5.59E-044.06E-0500.028ACME (treated)1.07E-021.23E-030.020.031ADE (control)1.13E-021.89E-030.020.024Prop. mediated (control)4.60E-025.08E-040.240.052Prop. mediated (treated)5.61E-044.02E-0500.028ADE (average)1.07E-021.23E-030.020.028Prop. mediated (treated)4.62E-02-5.08E-040.020.028Prop. mediated (treated)1.07E-021.23E-030.020.028Prop. mediated (average)1.07E-021.23E-030.020.028Prop. mediated (average)1.07E-021.23E-030.020.031Prop. mediated (average)1.07E-021.23E-030.020.031Prop. mediated (average)4.62E-02-5.08E-040.0240.052Prop. mediated (average)4.62E-02-5.08E-040.0240.052Prop. mediated (average)4.62E-02-5.08E-040.0240.052Prop. mediated (average)4.62E-02-5.08E-040.0240.052		Prop. mediated (treated)	0.044021	0.002888	0.13	0.0268
ADE (average)0.0036150.00501600.0004Prop. mediated (average)0.0439210.0028830.130.0268PHQ-9 score		ACME (average)	-0.000176	-0.000405	0	0.0268
Prop. mediated (average)0.0439210.0028830.130.0268PHQ-9 score <t< td=""><td rowspan="10"></td><td>ADE (average)</td><td>-0.003615</td><td>-0.005016</td><td>0</td><td>0.0004</td></t<>		ADE (average)	-0.003615	-0.005016	0	0.0004
PHQ-9 scoreImage: controlImage: controlImage: controlACME (control)5.59E-043.99E-0500.028ACME (treated)5.63E-044.06E-0500.028ADE (control)1.07E-021.23E-030.020.031ADE (treated)1.07E-021.23E-030.020.024Total effect1.13E-021.89E-030.020.024Prop. mediated (control)4.60E-02-5.07E-040.240.052Prop. mediated (treated)4.64E-02-5.08E-040.020.028ACME (average)5.61E-044.02E-0500.028Prop. mediated (average)4.62E-02-5.08E-040.020.031Prop. mediated (average)4.62E-02-5.08E-040.240.052Prop. mediated (average)4.62E-02-5.08E-040.240.052Prop. mediated (average)4.62E-02-5.08E-040.240.052Prop. mediated (average)4.62E-02-5.08E-040.240.052Prop. mediated (average)4.62E-02-5.08E-040.240.052		Prop. mediated (average)	0.043921	0.002883	0.13	0.0268
ACME (control)5.59E-043.99E-0500.028ACME (treated)5.63E-044.06E-0500.028ADE (control)1.07E-021.23E-030.020.031ADE (treated)1.07E-021.23E-030.020.031Total effect1.13E-021.89E-030.020.024Prop. mediated (control)4.60E-02-5.07E-040.240.052Prop. mediated (treated)5.61E-044.02E-0500.028ADE (average)5.61E-041.23E-030.020.031Prop. mediated (average)4.62E-02-5.08E-040.020.031Prop. mediated (average)4.62E-02-5.08E-040.240.052Prop. mediated (average)4.62E-02-5.08E-040.020.031Prop. mediated (average)4.62E-02-5.08E-040.240.052Prop. mediated (average)4.62E-02-5.08E-040.240.052		PHQ-9 score				
ACME (treated) 5.63E-04 4.06E-05 0 0.028   ADE (control) 1.07E-02 1.23E-03 0.02 0.031   ADE (treated) 1.07E-02 1.23E-03 0.02 0.031   Total effect 1.13E-02 1.89E-03 0.02 0.024   Prop. mediated (control) 4.60E-02 -5.07E-04 0.24 0.052   Prop. mediated (treated) 4.64E-02 -5.08E-04 0.24 0.052   ADE (average) 5.61E-04 4.02E-05 0 0.028   ADE (average) 1.07E-02 1.23E-03 0.02 0.031   Prop. mediated (average) 5.61E-04 4.02E-05 0 0.028   ADE (average) 1.07E-02 1.23E-03 0.02 0.031   Prop. mediated (average) 4.62E-02 -5.08E-04 0.024 0.052		ACME (control)	5.59E-04	3.99E-05	0	0.028
ADE (control) 1.07E-02 1.23E-03 0.02 0.031   ADE (treated) 1.07E-02 1.23E-03 0.02 0.031   Total effect 1.13E-02 1.89E-03 0.02 0.024   Prop. mediated (control) 4.60E-02 -5.07E-04 0.24 0.052   Prop. mediated (treated) 4.64E-02 -5.08E-04 0.24 0.052   ACME (average) 5.61E-04 4.02E-05 0 0.028   ADE (average) 1.07E-02 1.23E-03 0.02 0.031   Prop. mediated (average) 4.62E-02 -5.08E-04 0.02 0.031   Prop. mediated (average) 4.62E-02 -5.08E-04 0.02 0.031   Prop. mediated (average) 4.62E-02 -5.08E-04 0.02 0.031		ACME (treated)	5.63E-04	4.06E-05	0	0.028
ADE (treated) 1.07E-02 1.23E-03 0.02 0.031   Total effect 1.13E-02 1.89E-03 0.02 0.024   Prop. mediated (control) 4.60E-02 -5.07E-04 0.24 0.052   Prop. mediated (treated) 4.64E-02 -5.08E-04 0.24 0.052   ACME (average) 5.61E-04 4.02E-05 0 0.028   ADE (average) 1.07E-02 1.23E-03 0.02 0.031   Prop. mediated (average) 4.62E-02 -5.08E-04 0.24 0.052		ADE (control)	1.07E-02	1.23E-03	0.02	0.031
Total effect   1.13E-02   1.89E-03   0.02   0.024     Prop. mediated (control)   4.60E-02   -5.07E-04   0.24   0.052     Prop. mediated (treated)   4.64E-02   -5.08E-04   0.24   0.052     ACME (average)   5.61E-04   4.02E-05   0   0.028     ADE (average)   1.07E-02   1.23E-03   0.02   0.031     Prop. mediated (average)   4.62E-02   -5.08E-04   0.24   0.052		ADE (treated)	1.07E-02	1.23E-03	0.02	0.031
Prop. mediated (control)   4.60E-02   -5.07E-04   0.24   0.052     Prop. mediated (treated)   4.64E-02   -5.08E-04   0.24   0.052     ACME (average)   5.61E-04   4.02E-05   0   0   0.028     ADE (average)   1.07E-02   1.23E-03   0.02   0.031     Prop. mediated (average)   4.62E-02   -5.08E-04   0.24   0.052		Total effect	1.13E-02	1.89E-03	0.02	0.024
Prop. mediated (treated)   4.64E-02   -5.08E-04   0.24   0.052     ACME (average)   5.61E-04   4.02E-05   0   0.028     ADE (average)   1.07E-02   1.23E-03   0.02   0.031     Prop. mediated (average)   4.62E-02   -5.08E-04   0.24   0.052		Prop. mediated (control)	4.60E-02	-5.07E-04	0.24	0.052
ACME (average)   5.61E-04   4.02E-05   0   0.028     ADE (average)   1.07E-02   1.23E-03   0.02   0.031     Prop. mediated (average)   4.62E-02   -5.08E-04   0.24   0.052		Prop. mediated (treated)	4.64E-02	-5.08E-04	0.24	0.052
ADE (average)   1.07E-02   1.23E-03   0.02   0.031     Prop. mediated (average)   4.62E-02   -5.08E-04   0.24   0.052		ACME (average)	5.61E-04	4.02E-05	0	0.028
Prop. mediated (average)   4.62E-02   -5.08E-04   0.24   0.052		ADE (average)	1.07E-02	1.23E-03	0.02	0.031
		Prop. mediated (average)	4.62E-02	-5.08E-04	0.24	0.052

TABLE 12 Mediating effects of albumin on the relationship of cognitive function and depression scores with the risk of nocturia in females.

Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
Hemoglobin	DWRS				
	ACME (control)	-0.00026	-0.000728	0	0.096
	ACME (treated)	-0.00026	-0.00073	0	0.096
	ADE (control)	-0.00476	-0.00868	0	0.036
	ADE (treated)	-0.004761	-0.008681	0	0.036
	Total effect	-0.00502	-0.00896	0	0.028
	Prop. mediated (control)	0.045988	-0.017433	0.28	0.12
	Prop. mediated (treated)	0.046083	-0.017432	0.28	0.12
	ACME (average)	-0.00026	-0.000729	0	0.096
	ADE (average)	-0.004761	-0.008681	0	0.036
	Prop. mediated (average)	0.046036	-0.017432	0.28	0.12
	AFS				
	ACME (control)	-0.000303	-0.000808	0	0.093
	ACME (treated)	-0.000304	-0.000809	0	0.093
	ADE (control)	-0.005519	-0.010449	0	0.034
	ADE (treated)	-0.005519	-0.01045	0	0.034
	Total effect	-0.005823	-0.010784	0	0.027
	Prop. mediated (control)	0.046852	-0.014976	0.28	0.118
	Prop. mediated (treated)	0.046883	-0.014993	0.28	0.118
	ACME (average)	-0.000303	-0.000809	0	0.093
	ADE (average)	-0.005519	-0.01045	0	0.034
	Prop. mediated (average)	0.046867	-0.014984	0.28	0.118
	DSS				
	ACME (control)	-0.000203	-0.000519	0	0.1532
	ACME (treated)	-0.000203	-0.00052	0	0.1532
	ADE (control)	-0.00324	-0.004886	0	0.0008
	ADE (treated)	-0.003241	-0.004886	0	0.0008
	Total effect	-0.003444	-0.005039	0	0.0008
	Prop. mediated (control)	0.056314	-0.022787	0.21	0.154
	Prop. mediated (treated)	0.056417	-0.022814	0.21	0.154
	ACME (average)	-0.000203	-0.000519	0	0.1532
	ADE (average)	-0.003241	-0.004886	0	0.0008
	Prop. mediated (average)	0.056365	-0.0228	0.21	0.154
	PHQ-9 score				
	ACME (control)	0.000244	-0.00011	0	0.22
	ACME (treated)	0.000247	-0.000112	0	0.22
	ADE (control)	0.014503	0.008395	0.02	<2e-16
	ADE (treated)	0.014506	0.0084	0.02	<2e-16
	Total effect	0.01475	0.008664	0.02	<2e-16
	Prop. mediated (control)	0.013558	-0.007588	0.06	0.22
	Prop. mediated (treated)	0.013745	-0.007703	0.06	0.22
	ACME (average)	0.000246	-0.000111	0	0.22
	ADE (average)	0.014504	0.008397	0.02	<2e-16
	Prop. mediated (average)	0.013651	-0.007646	0.06	0.22

TABLE 13 Mediating effects of hemoglobin on the relationship of cognitive function and depression scores with the risk of nocturia in 60–69 years.

Mediated	Exposure	Estimate	95% CI lower	95% Ci upper	<i>p</i> -Value
Hemoglobin	DWRS				
	ACME (control)	-0.000199	-0.000851	0	0.52
	ACME (treated)	-0.000199	-0.000852	0	0.52
	ADE (control)	-0.000273	-0.00495	0	0.91
	ADE (treated)	-0.000273	-0.00495	0	0.91
	Total effect	-0.000472	-0.005173	0	0.84
	Prop. mediated (control)	0.027307	-2.046913	1.99	0.87
	Prop. mediated (treated)	0.02738	-2.046584	1.99	0.87
	ACME (average)	-0.000199	-0.000852	0	0.52
	ADE (average)	-0.000273	-0.00495	0	0.91
	Prop. mediated (average)	0.027343	-2.046749	1.99	0.87
	AFS				
	ACME (control)	-0.000794	-0.001768	0	0.042
	ACME (treated)	-0.000797	-0.001777	0	0.042
	ADE (control)	-0.004317	-0.009891	0	0.156
	ADE (treated)	-0.00432	-0.009897	0	0.156
	Total effect	-0.005114	-0.01058	0	0.097
	Prop. mediated (control)	0.137764	-0.518599	1.17	0.129
	Prop. mediated (treated)	0.138198	-0.518758	1.17	0.129
	ACME (average)	-0.000796	-0.001771	0	0.042
	ADE (average)	-0.004319	-0.009894	0	0.156
	Prop. mediated (average)	0.137981	-0.518678	1.17	0.129
	DSS				
	ACME (control)	-0.000646	-0.001092	0	<2e-16
	ACME (treated)	-0.000648	-0.001094	0	<2e-16
	ADE (control)	-0.002282	-0.004097	0	0.0284
	ADE (treated)	-0.002283	-0.0041	0	0.0284
	Total effect	-0.002929	-0.004674	0	0.0052
	Prop. mediated (control)	0.215117	0.083853	0.72	0.0052
	Prop. mediated (treated)	0.215622	0.084378	0.72	0.0052
	ACME (average)	-0.000647	-0.001093	0	<2e-16
	ADE (average)	-0.002283	-0.004099	0	0.0284
	Prop. mediated (average)	0.215369	0.084088	0.72	0.0052
	PHQ-9 score				
	ACME (control)	0.000156	-0.000933	0	0.771
	ACME (treated)	0.000156	-0.000935	0	0.771
	ADE (control)	0.012705	-0.000487	0.03	0.058
	ADE (treated)	0.012706	-0.000487	0.03	0.058
	Total effect	0.012861	-0.000356	0.03	0.058
	Prop. mediated (control)	0.010829	-0.181025	0.23	0.773
	Prop. mediated (treated)	0.010854	-0.18098	0.23	0.773
	ACME (average)	0.000156	-0.000934	0	0.771
	ADE (average)	0.012705	-0.000487	0.03	0.058
	Prop. mediated (average)	0.010842	-0.181003	0.23	0.773

TABLE 14 Mediating effects of hemoglobin on the relationship of cognitive function and depression scores with the risk of nocturia in 70–80 years.

Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
Albumin	DWRS				
	ACME (control)	-0.000216	-0.000673	0	0.171
	ACME (treated)	-0.000216	-0.000675	0	0.171
	ADE (control)	-0.005368	-0.009227	0	0.018
	ADE (treated)	-0.005369	-0.009228	0	0.018
	Total effect	-0.005585	-0.009448	0	0.013
	Prop. mediated (control)	0.032989	-0.017131	0.21	0.18
	Prop. mediated (treated)	0.033111	-0.017189	0.21	0.18
	ACME (average)	-0.000216	-0.000675	0	0.171
	ADE (average)	-0.005369	-0.009228	0	0.018
	Prop. mediated (average)	0.03305	-0.01716	0.21	0.18
	AFS				
	ACME (control)	-0.00027	-0.000793	0	0.11
	ACME (treated)	-0.00027	-0.000793	0	0.11
	ADE (control)	-0.005106	-0.010247	0	0.058
	ADE (treated)	-0.005106	-0.010248	0	0.058
	Total effect	-0.005376	-0.010477	0	0.046
	Prop. mediated (control)	0.043414	-0.04173	0.38	0.148
	Prop. mediated (treated)	0.043398	-0.041686	0.38	0.148
	ACME (average)	-0.00027	-0.000793	0	0.11
	ADE (average)	-0.005106	-0.010247	0	0.058
	Prop. mediated (average)	0.043406	-0.041708	0.38	0.148
	DSS				
	ACME (control)	-0.000148	-0.000397	0	0.1344
	ACME (treated)	-0.000148	-0.000398	0	0.1344
	ADE (control)	-0.003148	-0.004814	0	0.0016
	ADE (treated)	-0.003148	-0.004814	0	0.0016
	Total effect	-0.003296	-0.004955	0	0.0012
	Prop. mediated (control)	0.042024	-0.013246	0.16	0.1356
	Prop. mediated (treated)	0.042113	-0.013302	0.16	0.1356
	ACME (average)	-0.000148	-0.000398	0	0.1344
	ADE (average)	-0.003148	-0.004814	0	0.0016
	Prop. mediated (average)	0.042069	-0.013274	0.16	0.1356
	PHQ-9 score				
	ACME (control)	0.000348	-0.000215	0	0.22
	ACME (treated)	0.000353	-0.000219	0	0.22
	ADE (control)	0.014311	0.00846	0.02	<2e-16
	ADE (treated)	0.014316	0.008463	0.02	<2e-16
	Total effect	0.014664	0.008748	0.02	<2e-16
	Prop. mediated (control)	0.02106	-0.015754	0.08	0.22
	Prop. mediated (treated)	0.02137	-0.015896	0.08	0.22
	ACME (average)	0.000351	-0.000217	0	0.22
	ADE (average)	0.014313	0.008462	0.02	<2e-16
	Prop. mediated (average)	0.021215	-0.015814	0.08	0.22

TABLE 15 Mediating effects of albumin on the relationship of cognitive function and depression scores with the risk of nocturia in 60–69 years.

Mediated	Exposure	Estimate	95% CI lower	95% Cl upper	<i>p</i> -Value
Albumin	DWRS				
	ACME (control)	-0.000442	-0.001075	0	0.036
	ACME (treated)	-0.000442	-0.001075	0	0.036
	ADE (control)	0.000201	-0.004343	0	0.947
	ADE (treated)	0.000201	-0.004343	0	0.947
	Total effect	-0.000241	-0.004788	0	0.929
	Prop. mediated (control)	0.044816	-2.736136	2.46	0.931
	Prop. mediated (treated)	0.044965	-2.736068	2.46	0.931
	ACME (average)	-0.000442	-0.001075	0	0.036
	ADE (average)	0.000201	-0.004343	0	0.947
	Prop. mediated (average)	0.044891	-2.736102	2.46	0.931
	AFS				
	ACME (control)	-0.000618	-0.001394	0	0.02
	ACME (treated)	-0.00062	-0.001399	0	0.02
	ADE (control)	-0.004113	-0.009793	0	0.19
	ADE (treated)	-0.004115	-0.009797	0	0.19
	Total effect	-0.004733	-0.010327	0	0.13
	Prop. mediated (control)	0.112048	-0.724116	1.22	0.14
	Prop. mediated (treated)	0.11233	-0.724172	1.22	0.14
	ACME (average)	-0.000619	-0.001397	0	0.02
	ADE (average)	-0.004114	-0.009795	0	0.19
	Prop. mediated (average)	0.112189	-0.724144	1.22	0.14
	DSS				
	ACME (control)	-0.000238	-0.000546	0	0.026
	ACME (treated)	-0.000238	-0.000547	0	0.026
	ADE (control)	-0.002495	-0.004327	0	0.026
	ADE (treated)	-0.002496	-0.004328	0	0.026
	Total effect	-0.002733	-0.004538	0	0.015
	Prop. mediated (control)	0.080632	0.003467	0.38	0.041
	Prop. mediated (treated)	0.080786	0.003472	0.38	0.041
	ACME (average)	-0.000238	-0.000547	0	0.026
	ADE (average)	-0.002495	-0.004328	0	0.026
	Prop. mediated (average)	0.080709	0.00347	0.38	0.041
	PHQ-9 score				
	ACME (control)	0.000692	0.0000294	0	0.036
	ACME (treated)	0.000694	0.0000294	0	0.036
	ADE (control)	0.0121	-0.00149	0.03	0.082
	ADE (treated)	0.0121	-0.00149	0.03	0.082
	Total effect	0.0128	-0.000736	0.03	0.064
	Prop. mediated (control)	0.0487	-0.121	0.47	0.1
	Prop. mediated (treated)	0.0489	-0.121	0.47	0.1
	ACME (average)	0.000693	0.0000294	0	0.036
	ADE (average)	0.0121	-0.00149	0.03	0.082
	Prop. mediated (average)	0.0488	-0.121	0.47	0.1

TABLE 16 Mediating effects of albumin on the relationship of cognitive function and depression scores with the risk of nocturia in 70–80 years.

an increased risk of nocturia. In addition, we found different threshold effects between cognitive function/depression scores and nocturia risk, and keeping scores below the threshold could reduce the incidence of nocturia. Despite the absence of male/female differences in disease prevalence, there were male/female differences in the association of depression and cognitive function on nocturia risk. For instance, AFS, DSS, and PHQ-9 scores were significantly correlated with nocturia risk in women, whereas only PHQ-9 scores were significantly associated with nocturia in men. However, the mechanisms by which this occurs are unclear.

Depression was also a major public health problem worldwide (45). Nocturia was significantly associated with sleep disturbances in a bidirectional manner. Specifically, baseline nocturia was linked to new-onset sleep disturbances (OR = 1.49), while poor baseline sleep quality was associated with the development of new-onset nocturia (OR = 1.26). This effect was more pronounced among women and individuals under the age of 50 (46). Furthermore, sleep disruption may serve as an important mediator in the development of depression (47, 48). In our cohort, depression was significantly associated with nocturia in older adults, consistent with findings in young adults (49). Moreover, there were no male/female differences in the association between depression and nocturia risk. Little is known about the association between cognitive function and nocturia risk. We examined the association of TWRS, AFS, and DSS with nocturia risk and found that AFS, and DSS were associated with the risk of nocturia in women but not in men.

Nutritional status is linked with nocturia, depression, and cognitive function (50–52). We investigated the mediating effect of ALB and HGB on the association between nocturia, depression, and cognitive function. The results suggest that nutritional status partially mediates the relationship between nocturia risk, depression, and cognitive function in women and the association between nocturia risk and depression in men.

Our results showed a strong association between albumin and nocturia and partially mediate the association between cognitive function/depression and nocturia. Chuang et al. (53) found in their study on the correlation between nocturia and cirrhosis that the average albumin level of patients with nocturia and urinary incontinence was  $3.85 \pm 0.63$  g/dl, which was lower than that of the general population. Low albumin levels lead to decreased osmotic pressure, eliminating compensatory diuretic effects, and increased urine excretion (54). On the other hand, there was a significant association between albumin and cholinesterase, which affected bladder function (55, 56).

Hemoglobin concentration was a major factor in determining the delivery of oxygen to tissues (57). While hypoxia may lead to an increase in hemoglobin compensatory (58), malnutrition often resulted in insufficient hemoglobin synthesis raw materials, leaving tissues in a hypoxic state. Andersson et al. (59) found that bladder ischemia and hypoxia may be an important factor affecting bladder function. Therefore, improving anemia and oxygenation by increasing hemoglobin raw material intake may improve the incidence and symptoms of nocturia to some extent.

Currently, research had demonstrated that the mechanism of nocturia in the elderly varies between male/females. In women, the risk of nocturia was linked to a diminished circadian urination rhythm. Specifically, nocturia in older women was associated with reduced estrogen levels and impaired pelvic floor function (60). Notably, the risk of nocturia decreased by 25% (OR = 0.75) in the tertile group with the highest Free Androgen Index (FAI) (61, 62). In men, nocturia was significantly associated with testosterone deficiency (TD), with an odds ratio (OR) of 2.45 for TD and nocturia in patients over 60 years old with cardiovascular disease (CVD) (63, 64). Furthermore, differences exist in the mechanisms underlying bladder dysfunction. Older women were more likely to experience reduced bladder capacity (dBC, OR = 3.00), whereas men exhibit nocturnal bladder overactivity (dNBC, OR = 10.12) (65). Our results suggested that malnutrition also played a role in the onset of nocturia. And there were significant male/female differences. Older women typically exhibited a significantly higher risk of malnutrition compared to their male counterparts. A study conducted in the Basque Country of Spain revealed that the prevalence of malnutrition among women was 16.4% (data for men were inconclusive), with up to 47.5% being at risk (66). Likewise, within the community-dwelling older population, women are eight times more likely to be at risk of malnutrition than men (OR = 8) (67). But in rural Ethiopia, malnutrition rates of 34% for men over 65 and 25% for women show the opposite trend (68).

The study has limitations. First, the experimental design was retrospective. Therefore, longitudinal studies are necessary to confirm our findings. Second, the study did not assess the causal relationship between nocturia, depression, and cognitive function. Third, the effects of other nutritional indicators were not evaluated.

In conclusion, the results suggest that depression and CI are positively significantly associated with the risk of nocturia, especially in women. ALB and HGB levels partially mediate the association between nocturia, depression, and CI in older adults. Thus, improving nutrition may reduce the risk of nocturia, depression, and CI.

# Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: National Health and Nutrition Examination Survey.

# **Ethics statement**

The studies involving human participants were reviewed and approved by NCHS of the CDC. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

# Author contributions

YX: Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing. XW: Data curation, Formal analysis, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. GW: Data curation, Formal analysis, Investigation, Software, Validation, Writing – original draft, Writing – review & editing. WW: Conceptualization, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. NL: Conceptualization, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

# Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# References

1. Ahmad T, Khan M, Al-Omari B. Mapping the global literature output on nocturia: a bibliometric and visualized analysis. *Medicine*. (2022) 101:e29455. doi: 10.1097/MD.000000000029455

2. Everaert K, Bou Kheir G, Vande Walle J, Verbakel I, Hervé F, NOPIA Research Group. Introductory editorial: lifelong LUTS, a matter of transition? *Neurourol Urodyn.* (2024) 43:1037–9. doi: 10.1002/nau.25301

3. Bozkurt O, Irer B, Kizilay F, Erbatu O, Sen V, Cinar O, et al. Mechanisms and grading of nocturia: results from a multicentre prospective study. *Int J Clin Pract.* (2021) 75:e13722. doi: 10.1111/ijcp.13722

4. Haddad R, Monaghan TF, Joussain C, Phé V, Bower W, Roggeman S, et al. Nocturia in patients with cognitive dysfunction: a systematic review of the literature. *BMC Geriatr.* (2020) 20:230. doi: 10.1186/s12877-020-01622-8

5. Cheng W, Fan YH, Liou YJ, Hsu YT. The predictive factors of nocturia in young Asian adult males: an online survey. *Sci Rep.* (2021) 11:16218. doi: 10.1038/s41598-021-95836-4

6. Ma K, Chen C, Shen L, Tang P, Guan R. The relationship between nocturia and suicidal ideation: a study on the national health and nutrition survey data. *Neurourol Urodyn.* (2024) 43:2195–206. doi: 10.1002/nau.25537

7. Mikulska J, Juszczyk G, Gawrońska-Grzywacz M, Herbet M. HPA axis in the pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation. *Brain Sci.* (2021) 11:1298. doi: 10.3390/brainsci11101298

8. Manosso LM, Duarte LA, Martinello NS, Mathia GB, Réus GZ. Circadian rhythms and sleep disorders associated to major depressive disorder: pathophysiology and therapeutic opportunities. *CNS Neurol Disord Drug Targets*. (2024) 23:1085–100. doi: 10.2174/0118715273254093231020052002

9. Liu J, Chen K, Tang M, Mu Q, Zhang S, Li J, et al. Oxidative stress and inflammation mediate the adverse effects of cadmium exposure on all-cause and cause-specific mortality in patients with diabetes and prediabetes. *Cardiovasc Diabetol.* (2025) 24:145. doi: 10.1186/s12933-025-02698-5

10. Gottesman RF, Lutsey PL, Benveniste H, Brown DL, Full KM, Lee JM, et al. Impact of sleep disorders and disturbed sleep on brain health: a scientific statement from the American Heart Association. *Stroke.* (2024) 55:e61–76. doi: 10.1161/STR.00000000000453

11. Saleh-Ghadimi S, Dehghan P, Sarmadi B, Maleki P. Improvement of sleep by resistant dextrin prebiotic in type 2 diabetic women coincides with attenuation of metabolic endotoxemia: involvement of gut-brain axis. *J Sci Food Agric.* (2022) 102:5229–37. doi: 10.1002/jsfa.11876

12. Kupjetz M, Wences Chirino TY, Joisten N, Zimmer P. Kynurenine pathway dysregulation as a mechanistic link between cognitive impairment and brain damage: implications for multiple sclerosis. *Brain Res.* (2025) 1853:149415. doi: 10.1016/j.brainres.2024.149415

# **Generative AI statement**

The author(s) declare that no Gen AI was used in the creation of this manuscript.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2025. 1533683/full#supplementary-material

13. Li W, Yang L, Chen H, Miao J, Wang Y, Zhou C, et al. Depression, stress, and tryptophan metabolism through the kynurenine pathway: treatment strategies from the perspective of Chinese herbal medicine. *Metab Brain Dis.* (2024) 40:5. doi: 10.1007/s11011-024-01461-1

14. Kanova M, Kohout P. Tryptophan: a unique role in the critically ill. *Int J Mol Sci.* (2021) 22:11714. doi: 10.3390/ijms222111714

15. Lin F, Deng Y, Li J, Liu C, Xiao L. Oxidative stress and inflammatory factors mediate the association between dietary antioxidant intake and depressive symptoms in middle and old-aged individuals: a cross-sectional study from NHANES. *Gen Hosp Psychiatry.* (2024) 91:160–6. doi: 10.1016/j.genhosppsych.2024.10.016

 Zhu H, Tao R, Yu Q, Yu M, Zhou Y, Fu Q. The mediating roles of obesity indicators and serum albumin in the association of DEET exposure with depression and sleep disorders in adults: evidence from NHANES 2007-2016. *BMC Public Health*. (2025) 25:1658. doi: 10.1186/s12889-025-22880-4

17. Gong S, Bou Kheir G, Kabarriti A, Khosla L, Gong F, Van Laecke E, et al. 'Nocturomics': transition to omics-driven biomarkers of nocturia, a systematic review and future prospects. *BJU Int.* (2023) 131:675–84. doi: 10.1111/bju.15975

18. Wang H, Lv Y, Ti G, Ren G. Association of low-carbohydrate-diet score and cognitive performance in older adults: national health and nutrition examination survey (NHANES). *BMC Geriatr.* (2022) 22:983. doi: 10.1186/s12877-022-03 607-1

19. Wei B, Dong Q, Ma J, Zhang A. The association between triglyceride-glucose index and cognitive function in nondiabetic elderly: NHANES 2011-2014. *Lipids Health Dis.* (2023) 22:188. doi: 10.1186/s12944-023-01959-0

20. Liu L. Exploring the association between overactive bladder (OAB) and cognitive decline: mediation by depression in elderly adults, a NHANES weighted analysis. *Sci Rep.* (2025) 15:3669. doi: 10.1038/s41598-025-86267-6

21. Gasca-Salas C, Duff-Canning S, McArthur E, Armstrong MJ, Fox S, Meaney CA, et al. Predictors of cognitive change in Parkinson disease: a 2-year follow-up study. *Alzheimer Dis Assoc Disord.* (2023) 37:335–42. doi: 10.1097/WAD.0000000000 00576

22. Park KW, Ko JH, Choi N, Jo S, Park YJ, Lee EJ, et al. Cortical hypometabolism associated with cognitive impairment of multiple system atrophy. *Parkinsonism Relat Disord*. (2020) 81:151–6. doi: 10.1016/j.parkreldis.2020.10.039

23. Liang Y, Wang J, Wang T, Li H, Yin C, Liu J, et al. Moderate selenium mitigates hand grip strength impairment associated with elevated blood cadmium and lead levels in middle-aged and elderly individuals: insights from NHANES 2011-2014. *Front Pharmacol.* (2023) 14:1324583. doi: 10.3389/fphar.2023.1324583

24. Wang Y, Meng T, Yang W, Yan M, Su X, Wang X, et al. Association of grip strength and comorbidities with all-cause mortality in the older hypertensive adults. *Front Public Health.* (2023) 11:1162425. doi: 10.3389/fpubh.2023.1162425

25. Hou W, Chen S, Zhu C, Gu Y, Zhu L, Zhou Z. Associations between smoke exposure and osteoporosis or osteopenia in a US NHANES population of elderly individuals. *Front Endocrinol.* (2023) 14:1074574. doi: 10.3389/fendo.2023.1074574

26. Cheng L, Wang S. Correlation between bone mineral density and sarcopenia in US adults: a population-based study. *J Orthop Surg Res.* (2023) 18:588. doi: 10.1186/s13018-023-04034-7

27. Hong Y, Chen X, Liu J. Analysis of factors associated with constipation in the population with obesity: evidence from the national health and nutrition examination survey. *Obes Facts.* (2024) 17:169–82. doi: 10.1159/000536318

28. Zhang Q, Xiao S, Jiao X, Shen Y. The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001-2018. *Cardiovasc Diabetol.* (2023) 22:279. doi: 10.1186/s12933-023-02030-z

29. Zhou W, Sun L, Zeng L, Wan L. Mediation of the association between sleep disorders and cardiovascular disease by depressive symptoms: an analysis of the national health and nutrition examination survey (NHANES) 2017-2020. *Prev Med Rep.* (2023) 33:102183. doi: 10.1016/j.pmedr.2023.102183

30. Rucker DD, Preacher KJ, Tormala ZL, Petty RE. Mediation analysis in social psychology: current practices and new recommendations. *Soc Personal Psychol Compass.* (2011) 5:359–71. doi: 10.1111/j.1751-9004.2011.00355.x

31. Hayes A. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. *Commun Monogr.* (2009) 76:408–20. doi: 10.1080/03637750903310360

32. Bliwise DL, Wagg A, Sand PK. Nocturia: a highly prevalent disorder with multifaceted consequences. *Urology*. (2019) 133S:3–13. doi: 10.1016/j.urology.2019.07.005

33. Tikkinen KA, Auvinen A, Johnson TM 2nd, Weiss JP, Keränen T, Tiitinen A, et al. A systematic evaluation of factors associated with nocturia–the population-based FINNO study. *Am J Epidemiol.* (2009) 170:361–8. doi: 10.1093/aje/kwp133

34. Hsieh CH, Kuo TC, Hsu CS, Chang ST, Lee MC. Nocturia among women aged 60 or older in Taiwan. Aust N Z J Obstet Gynaecol. (2008) 48:312-6. doi: 10.1111/j.1479-828X.2008.00870.x

35. Moriyama Y, Miwa K, Tanaka H, Fujihiro S, Nishino Y, Deguchi T. Nocturia in men less than 50 years of age may be associated with obstructive sleep apnea syndrome. *Urology.* (2008) 71:1096–8. doi: 10.1016/j.urology.2008.02.038

36. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. *Alzheimers Dement.* (2015) 11:718–26. doi: 10.1016/j.jalz.2015.05.016

37. Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. *Lancet Neurol.* (2014) 13:1017-28. doi: 10.1016/S1474-4422(14) 70172-3

38. Merrill L, Gonzalez EJ, Girard BM, Vizzard MA. Receptors, channels, and signalling in the urothelial sensory system in the bladder. *Nat Rev Urol.* (2016) 13:193–204. doi: 10.1038/nrurol.2016.13

39. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. *Nat Rev Neurosci.* (2008) 9:453–66. doi: 10.1038/nrn2401

40. Valentino RJ, Wood SK, Wein AJ, Zderic SA. The bladder-brain connection: putative role of corticotropin-releasing factor. *Nat Rev Urol.* (2011) 8:19–28. doi: 10.1038/nrurol.2010.203

41. Hou XH, Hyun M, Taranda J, Huang KW, Todd E, Feng D, et al. Central control circuit for context-dependent micturition. *Cell.* (2016) 167:73-86.e12. doi: 10.1016/j.cell.2016.08.073

42. Griffiths D. Neural control of micturition in humans: a working model. *Nat Rev Urol.* (2015) 12:695–705. doi: 10.1038/nrurol.2015.266

43. Xiao W, Jiao ZL, Senol E, Yao J, Zhao M, Zhao ZD, et al. Neural circuit control of innate behaviors. *Sci China Life Sci.* (2022) 65:466–99. doi: 10.1007/s11427-021-2043-2

44. Crowley SJ, Kanel P, Roytman S, Bohnen NI, Hampstead BM. Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson's disease. *Brain.* (2024) 147:1799–808. doi: 10.1093/brain/awad420

45. Daly M, Sutin AR, Robinson E. Depression reported by US adults in 2017-2018 and March and April 2020. J Affect Disord. (2021) 278:131-5. doi: 10.1016/j.jad.2020.09.065

46. Negoro H, Setoh K, Fukunaga A, Kawaguchi T, Funada S, Yoshino T, et al. Risk analyses of nocturia on incident poor sleep and vice versa: the Nagahama study. *Sci Rep.* (2023) 13:9495. doi: 10.1038/s41598-023-36707-y

47. Lai HH, Walker D, Elsouda D, Lockefeer A, Gallington K, Bacci ED. Sleep disturbance among adults with overactive bladder: a cross-sectional survey. *Urology*. (2023) 179:23–31. doi: 10.1016/j.urology.2023.06.014

48. Diaconu S, Irincu L, Ungureanu L, Ținț D, Falup-Pecurariu C. Nocturia and sleep in Parkinson's disease. *J Pers Med.* (2023) 13:1053. doi: 10.3390/jpm1307 1053

49. Breyer BN, Shindel AW, Erickson BA, Blaschko SD, Steers WD, Rosen RC. The association of depression, anxiety and nocturia: a systematic review. *J Urol.* (2013) 190:953–7. doi: 10.1016/j.juro.2013.03.126

50. Di Bello F, Napolitano L, Abate M, Collà Ruvolo C, Morra S, Califano G, et al. "Nocturia and obstructive sleep apnea syndrome: a systematic review". *Sleep Med Rev.* (2023) 69:101787. doi: 10.1016/j.smrv.2023.101787

51. Murayama H, Shinkai S, Nishi M, Taniguchi Y, Amano H, Seino S, et al. Albumin, hemoglobin, and the trajectory of cognitive function in community-dwelling older Japanese: a 13-year longitudinal study. *J Prev Alzheimers Dis.* (2017) 4:93–9. doi: 10.14283/jpad.2016.113

52. Xi L, Fang F, Zhou J, Xu P, Zhang Y, Zhu P, et al. Association of hemoglobin-tored blood cell distribution width ratio and depression in older adults: a cross sectional study. J Affect Disord. (2024) 344:191–7. doi: 10.1016/j.jad.2023.10.027

53. Chuang PH, Chang YH, Hsiao PJ, Chou EC. Diagnostic potential of low serum platelet, albumin and prolong PT-INR for overactive bladder and nocturia in chronic hepatitis-related liver cirrhosis. *J Clin Med.* (2021) 10:2838. doi: 10.3390/jcm10132838

54. Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management-a systematic review and meta-analysis. *Eur Urol.* (2012) 62:877–90. doi: 10.1016/j.eururo.2012.07.004

55. Nakahara T, Kubota Y, Sakamoto K, Ishii K. The role of cholinesterases in rat urinary bladder contractility. *Urol Res.* (2003) 31:223–6. doi: 10.1007/s00240-003-0326-1

56. Sugaya K, Onaga T, Nishijima S, Miyazato M, Oshiro Y, Hokama S, et al. Relationship between serum cholinesterase level and urinary bladder activity in patients with or without overactive bladder and/or neurogenic bladder. *Biomed Res.* (2007) 28:287–94. doi: 10.2220/biomedres.28.287

57. Ramanan M, Fisher N. The association between arterial oxygen tension, hemoglobin concentration, and mortality in mechanically ventilated critically ill patients. *Indian J Crit Care Med.* (2018) 22:477–84. doi: 10.4103/ijccm.IJCCM\_66\_18

58. Zhong R, Wu X, Liu Z, He Z, Zhang X, Liu J, et al. A study on the correlation between hemoglobin concentration and the storage quality of suspended red blood cells prepared from the whole blood of Tibetan male residents. *Front Med.* (2022) 9:1062778. doi: 10.3389/fmed.2022.1062778

59. Andersson KE, Boedtkjer DB, Forman A. The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction. *Ther Adv Urol.* (2017) 9:11–27. doi: 10.1177/1756287216675778

60. Yoshiyama A, Tsujimura A, Hiramatsu I, Morino J, Anno Y, Kurosawa M, et al. Circadian rhythm of voided volume, maximum flow rate, and voiding time evaluated by toilet uroflowmetry in hospitalized women with nocturia. *Urology*. (2023) 179:50–7. doi: 10.1016/j.urology.2023.06.008

61. Gao S, Fan L, He J, Liu H, Tian R. Investigating the link between free androgen index and nocturia in women: findings from national health and nutrition examination survey. *Neurourol Urodyn*. (2025) 44:728–35. doi: 10.1002/nau.70006

62. Pauwaert K, Goessaert AS, Robinson D, Cardozo L, Bower W, Calders P, et al. Nocturia in menopausal women: the link between two common problems of the middle age. *Int Urogynecol J.* (2024) 35:935–46. doi: 10.1007/s00192-024-05743-1

63. Kim SJ, Lee D, Park SG, Pak S, Lee YG, Cho ST. The association between testosterone deficiency and nocturia: insights from the national health and nutrition examination survey data set. *Neurourol Urodyn.* (2024) 43:486–93. doi:10.1002/nau.25371

64. Kao KW, Cheng W, Wu CJ, Fan YH. Nocturia independently predicts left ventricular hypertrophy and left atrial enlargement among patients with cardiac symptoms. *Sci Rep.* (2022) 12:14897. doi: 10.1038/s41598-022-19190-9

65. Yoon JH, Lee K, Park EJ, Kwon T, Park S, Moon KH, et al. Analysis of changes in the pathophysiology of nocturia according to the number of nocturia episode, age, and gender using frequency volume charts: a retrospective observational study. *Medicine*. (2022) 101:e31295. doi: 10.1097/MD.000000000031295

66. Larburu N, Artola G, Kerexeta J, Caballero M, Ollo B, Lando CM. Key factors and AI-based risk prediction of malnutrition in hospitalized older women. *Geriatrics.* (2022) 7:105. doi: 10.3390/geriatrics7050105

67. Rashid T, Zia S, Mughal S, Baloch AA, Abdul Rauf MU, Hasan SM. Prevalence of malnutrition and associated factors among the elderly with type 2 diabetes using MNA form. *J Nutr Metab.* (2025) 2025:2107146. doi: 10.1155/jnme/2107146

68. Zewdu E, Daniel L, Derso T, Ferede YM. Level of malnutrition and associated factors among community-dwelling rural older adults in Fogera Zuriya district, northwest Ethiopia. *Nutrition*. (2023) 113:112085. doi: 10.1016/j.nut.2023.112085